Patient-specific iPSCs carrying an SFTPC mutation reveal the intrinsic alveolar epithelial dysfunction at the inception of interstitial lung disease by Alysandratos, Konstantinos-Dionysios et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
8-31-2021 
Patient-specific iPSCs carrying an SFTPC mutation reveal the 
intrinsic alveolar epithelial dysfunction at the inception of 
interstitial lung disease 
Konstantinos-Dionysios Alysandratos 
Jennifer A Wambach 
F Sessions Cole 
et al 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Article
Patient-specific iPSCs carrying an SFTPC mutation
reveal the intrinsic alveolar epithelial dysfunction at
the inception of interstitial lung disease
Graphical abstract
Highlights
d Patient-specific iAEC2s serve as a human preclinical platform
for modeling ILD
d Patient-derived iAEC2s expressing mutant SFTPCI73T have
diminished progenitor capacity
d SFTPCI73T mutant iAEC2s display proteostasis perturbations
and metabolic reprogramming
d Mutant iAEC2s are an important proinflammatory hub via
activation of the NF-kB pathway
Authors
Konstantinos-Dionysios Alysandratos,
Scott J. Russo, Anton Petcherski, ...,







Alysandratos et al. differentiate patient-
specific iPSCs carrying the ILD-
associated SFTPCI73T variant and
syngeneic corrected iPSCs into alveolar
epithelial type 2 cells (iAEC2s). They find
that mutant iAEC2s demonstrate
proteostasis perturbations, altered
bioenergetic programs, and metabolic
reprogramming. They validate these
findings in vivo in primarymouse SftpcI73T
AEC2s.
Alysandratos et al., 2021, Cell Reports 36, 109636
August 31, 2021 ª 2021 The Author(s).
https://doi.org/10.1016/j.celrep.2021.109636 ll
Article
Patient-specific iPSCs carrying an SFTPCmutation
reveal the intrinsic alveolar epithelial dysfunction
at the inception of interstitial lung disease
Konstantinos-Dionysios Alysandratos,1,2 Scott J. Russo,3,4 Anton Petcherski,5 Evan P. Taddeo,5 Rebeca Acı́n-Pérez,5
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SUMMARY
Alveolar epithelial type 2 cell (AEC2) dysfunction is implicated in the pathogenesis of adult and pediatric
interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF); however, identification of
disease-initiating mechanisms has been impeded by inability to access primary AEC2s early on. Here, we
present a human in vitro model permitting investigation of epithelial-intrinsic events culminating in AEC2
dysfunction, using patient-specific induced pluripotent stem cells (iPSCs) carrying an AEC2-exclusive
disease-associated variant (SFTPCI73T). Comparing syngeneic mutant versus gene-corrected iPSCs after
differentiation into AEC2s (iAEC2s), we find that mutant iAEC2s accumulate large amounts of misprocessed
and mistrafficked pro-SFTPC protein, similar to in vivo changes, resulting in diminished AEC2 progenitor
capacity, perturbed proteostasis, altered bioenergetic programs, time-dependent metabolic reprogramming,
and nuclear factor kB (NF-kB) pathway activation. Treatment of SFTPCI73T-expressing iAEC2s with hydroxy-
chloroquine, amedication used in pediatric ILD, aggravates the observed perturbations. Thus, iAEC2s provide
a patient-specific preclinical platform for modeling the epithelial-intrinsic dysfunction at ILD inception.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is the most common and
severe form of idiopathic interstitial pneumonia and is character-
ized by relentless fibrosis leading to disruption of the gas ex-
change unit and death within an average of 4 years from the
time of diagnosis (Lederer and Martinez, 2018; Raghu et al.,
2014, 2016; Travis et al., 2013). The poorly understood patho-
genesis of IPF, in part due to the lack of human disease models,
has been a major hurdle in developing effective therapies.
Although a broad, established literature has focused on the
role of lung fibroblasts in perpetuating IPF at later disease
stages, factors that initiate or drive disease onset at early stages
have been particularly hard to identify. With the advent of
genome-wide association studies and intensive study of familial
forms of pulmonary fibrosis, the lung epithelium has been
increasingly implicated as a potential proximal disease driver
with variants in gene loci expressed in lung epithelia having
been associated with disease risk (Garcia, 2018; Kropski et al.,
2015).
Of the many types of epithelia present in the lung, dysfunction
of the alveolar epithelial type 2 cell (AEC2), in particular, has been
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repeatedly implicated in the pathogenesis of interstitial lung dis-
ease (ILD), including IPF (Barkauskas and Noble, 2014; Katzen-
stein, 1985; Winters et al., 2019; Selman and Pardo, 2014).
Determining how AEC2 dysfunction leads to disease in humans,
however, has been challenging to date. For example, studying
AEC2 pathophysiology in primary human cells has been limited
by difficulty in accessing patient samples and the tendency of
AEC2s to lose their identity in culture (Borok et al., 1998; Foster
et al., 2007), particularly in the absence of mesenchymal feeders
(Barkauskas et al., 2013).
An ideal model of human AEC2 dysfunction would allow the
study of disease by utilizing patient-derived cells to reveal a
cascade of mechanistic events associated with the inception
as well as progression of lung disease. Here, we present such
a model of disease inception employing induced pluripotent
stem cells (iPSCs) that we have derived from patients with ILD
in order to generate an inexhaustible supply of AEC2-like cells
in vitro to study the epithelial-intrinsic events that lead to specific
AEC2 perturbations that are then validated in one of the donor
patient’s tissue in vivo. To ensure examination of only the cell
type responsible for initiating disease without the potential con-
founding or secondary effects of co-cultured supporting cells,
we have developed an epithelial-only model composed solely
of purified AEC2-like cells that can be propagated indefinitely
without any supporting cells, and we have chosen to focus
here on a disease-associated variant in the surfactant protein
C (SFTPC) gene because it is known to be expressed postnatally
solely in AEC2s and can be gene-edited to provide syngeneic
comparator cells, thus providing a reductionist model amenable
to discerning the putative epithelial-intrinsic events associated
with disease inception.
Heterozygous mutations in SFTPC have been associated with
both sporadic and familial pulmonary fibrosis as well as child-
hood interstitial lung disease (chILD) (Cottin et al., 2011; Crossno
et al., 2010; Mulugeta et al., 2015; Nogee et al., 2001; Ono et al.,
2011; Thomas et al., 2002; van Moorsel et al., 2010). Among the
more than 60 SFTPC variants described to date, the missense
mutation g.1286T > C, resulting in substitution of threonine for
isoleucine at amino acid 73 in the pro-SFTPC protein
(SFTPCI73T), is the focus of our study because it is the predom-
inant disease-associated SFTPC variant. Two recent mouse ge-
netic models, conditionally expressing mutant SFTPC (p.I73T
and p.C121G, respectively) from the endogenous Sftpc locus,
resulted in polycellular alveolitis and pulmonary fibrosis (Katzen
et al., 2019; Nureki et al., 2018). Although previous studies
have shown that expression of SFTPCI73T in vitro (Beers et al.,
2011; Hawkins et al., 2015) or in mice in vivo (Nureki et al.,
2018) leads to SFTPC proprotein misprocessing and lung
fibrosis, the cellular mechanisms by which dysfunctional
AEC2s initiate the fibrotic cascade in humans remain elusive.
Most importantly, elucidating the molecular pathogenesis of hu-
man AEC2 dysfunction caused by SFTPCI73T is likely to inform
the broader mechanisms by which AEC2 dysfunction leads
to IPF.
A critical role for AEC2s in ILD initiation is concordant with their
essential role in maintaining distal lung homeostasis. AEC2s
function both as facultative progenitors of alveoli as well as
secretory cells in the distal lung. In order to meet the high meta-
bolic demands posed by these functions, AEC2s have a larger
number of mitochondria compared to other lung cell types (Mas-
saro et al., 1975), and alterations in mitochondrial function, as
observed in our model, are likely to lead to a variety of perturbed
metabolic programs. Indeed, accumulation of dysmorphic and
dysfunctional mitochondria in association with impaired auto-
phagy and mitophagy has been shown in AEC2s from IPF lungs
(Bueno et al., 2015). Furthermore, thyroid hormone-mediated
restoration of mitochondrial function and mitophagy was
recently shown to blunt pulmonary fibrosis in two mouse models
of pulmonary fibrosis (Yu et al., 2018).
Because there are significant differences between murine and
human pulmonary fibrosis, there is a pressing need for reliable
human preclinical disease models that would not only provide
further insight into the pathophysiology of human AEC2 dysfunc-
tion at ILD inception, but would also serve as a platform to test
the safety and efficacy of unproven currently used as well as
novel therapies. Here, we show that SFTPCI73T-expressing
human iPSC-derived AEC2s (hereafter iAEC2s) provide further
insights into disease pathogenesis, allow assessment of
currently used unproven treatments, and have the potential to
serve as a platform for testing novel therapeutics.
RESULTS
Generation of patient-specific iPSC lines and their
differentiation to alveolar epithelium
To examine the mechanisms leading to human AEC2 dysfunc-
tion, we generated patient-specific iPSC lines by reprogramming
dermal fibroblasts (SPC2) or peripheral blood mononuclear cells
(SPC6 and SPC7) from three individuals with lung disease who
were heterozygous for the most frequent disease-associated
SFTPC variant (SFTPCI73T/WT) (Figure 1A; Table S1). The SPC2
donor in particular suffered from severe ILD (Figure 1B and
detailed clinical phenotyping in Table S1) necessitating the
need for lung transplantation in early adolescence providing ac-
cess to histopathological specimens of diseased explanted lung
tissue (Figure 1C). The SPC6 and SPC7 donors also suffered
from ILD based on chest computed tomography (CT) imaging
(Figure S1A; Table S1). To overcome the hurdles imposed by
the high variance in differentiation efficiencies or cellular pheno-
types associated with different genetic backgrounds of iPSC
lines generated fromdistinct individuals (Bock et al., 2011; Boult-
ing et al., 2011; Kim et al., 2010) and to allow for purification of
specific cell types, we engineered gene-corrected syngeneic
lines by using activator-like effector nucleases (TALEN)-based
gene editing to knock in a tdTomato fluorescent reporter into
one allele of the endogenous SFTPC locus of the parental
SPC2 iPSC line. This resulted in generation of syngeneic cor-
rected (hereafter SFTPCtdT/WT) and mutant (hereafter
SFTPCI73T/tdT) iPSC lines, because the tdTomato cassette is fol-
lowed by a stop/polyA cassette, preventing expression of the
subsequent SFTPC coding sequence from the targeted allele
(Figure 1D). Thus, this targeting strategy was designed to result
in preparation of a reductionist model where only one SFTPC
allele would be expressed in each paired clone, enabling
study of only the mutant versus only the normal allele. It also
allowed tracking of SFTPCtdTomato+ cells as they emerge through









Figure 1. Generation of patient-specific iPSC lines and their differentiation to alveolar epithelium
(A) Schematic showing the generation of patient-specific iPSCs from dermal fibroblasts or peripheral blood mononuclear cells (PBMCs) from three individuals
carrying the most frequent SFTPC pathogenic variant (SFTPCI73T/WT).
(B) Chest CT of the SPC2 donor reveals diffuse ground glass opacities and traction bronchiectasis.
(C) H&E staining of the SPC2 donor lung explant shows end-stage lung disease with interstitial fibrosis, chronic inflammation, and alveolar remodeling with AEC2
hyperplasia and degenerating macrophages within the residual alveoli. Scale bar, 200 mm.
(D) Transcription activator-like effector nucleases (TALEN) targeting strategy and edited SFTPC loci post Cre-mediated antibiotic cassette excision.
(E) Schematic of directed differentiation protocol from iPSCs to day 30+ monolayered epithelial iAEC2 spheres (alveolospheres).
(F) Schematic of CHIR modulation to achieve iAEC2 maturation and representative flow cytometry dot plots (mean ± SD; n = 6 biological replicates of
independent differentiations).
(G) Dot plots depicting the normalized expression level of AEC2-marker genes in day 114 and day 131 SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s compared to day
0 iPSCs and week 21 human fetal distal lung (HFL) controls, by bulk RNA sequencing (boxplots represent mean ± SD; n = 3 experimental replicates of
independent wells of a differentiation).








Figure 2. Derivation of parallel self-renewing corrected (SFTPCtdT/WT) and mutant (SFTPCI73T/tdT) iAEC2s
(A) Representative flow cytometry dot plots of day 82 (p2), day 115 (p4), day 149 (p6), day 190 (p8), day 208 (p9), day 243 (p11), and day 285 (p13) SFTPCtdT/WT and
SFTPCI73T/tdT iAEC2s. MFI, mean fluorescence intensity.
(B) Representative live-cell imaging of SFTPCtdT/WT and SFTPCI73T/tdT alveolospheres (bright-field/tdTomato overlay; day 149). Scale bars, 500 mm.
(C) Graph showing yield per input tdT/WT or I73T/tdT SFTPCtdTomato+ cell sorted on day 51 and passaged without further sorting. **p < 0.01, ***p < 0.001, ****p <
0.0001 by unpaired, two-tailed Student’s t test.
(D) Bar graph shows retention of the AEC2 cell fate in SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s maintained in culture for 302 days, measured by flow cytometry as
the frequency of cells expressing the SFTPCtdTomato reporter.
(legend continued on next page)




in vitro directed differentiation and purification of corrected and
mutant SFTPCtdTomato+ putative iAEC2s for subsequent profiling.
To ensure that any findings from this single allele expression
model could be replicated in iAEC2s expressing two active
SFTPC alleles, as occurs in vivo, we also engineered an untar-
geted clone of the SPC2 line (hereafter SFTPCI73T/WT), which
then underwent footprint-free correction of the SFTPC variant
via CRISPR/Cas9 gene editing (hereafter SFTPCWT/WT) (Fig-
ure S1B). Furthermore, to ensure reproducibility across different
genetic backgrounds, we utilized the other two donor iPSC lines
(SPC6 and SPC7; clinical phenotyping in the Supplemental infor-
mation) to validate key observations made in the SPC2 iPSC
lines.
Derivation of parallel indefinitely self-renewing iAEC2s
Next, we used our previously published lung directed differenti-
ation protocol (Jacob et al., 2017, 2019) to generate corrected
and mutant iAEC2s (Figures 1E and 1F), with the goal of produc-
ing indefinitely self-renewing patient-specific cells for disease
modeling. Corrected and mutant SFTPCtdTomato+ iAEC2s were
sorted to purity for further replating, characterization of gene
expression (Figure 1G), and culture expansion as self-renewing
epithelial-only spheres without the need for subsequent cell sort-
ing (Figures 2A and 2B). The resulting iAEC2s maintained an
AEC2-specific transcriptomic profile (Figure 1G); however,
mutant iAEC2s demonstrated distinct morphologies and brighter
tdTomato reporter expression (Figures 2A and 2B and further
discussed below).
We sought to determine both the stability of SFTPC expres-
sion levels as well as the total cell yield arising during serial
passaging of mutant versus corrected iAEC2s in epithelial-
only 3D cultures. Over a 302-day period, we generated yields
of >1023 and >1015 corrected versus mutant iAEC2s per starting
sorted tdTomato+ cell, respectively (Figure 2C). Although yields
over this time period were significantly lower for mutant iAEC2s,
both lines maintained SFTPCtdTomato expression in 94% ± 0.3%
and 89.1% ± 1.9% of cells for at least 302 days andmaintained a
normal karyotype until at least day 214 (Figure 2D). In this self-re-
newing model, mutant iAEC2s demonstrated significantly lower
proliferation rates than corrected iAEC2s assessed by EdU
incorporation assays (Figure 2E) and no differences in apoptosis,
as measured by immunostaining for activated caspase-3 (Fig-
ure 2F). These results suggest SFTPC mutant iAEC2s have
diminished self-renewal capacity.
SFTPCI73T iAEC2s display altered apical-basal polarity
and aberrant protein trafficking and accumulate large
amounts of aberrantly processed SFTPC pro-protein
We further examined the impact of the SFTPCI73T mutation on
AEC2 morphology in vitro and in vivo. Although corrected
(SFTPCtdT/WT) iAEC2s formed monolayered epithelial spheres
(alveolospheres) in culture as expected (Jacob et al., 2017),
mutant (SFTPCI73T/tdT) iAEC2s lacked lumens and instead
formed ball-like structures when assessed by microscopy of
paraffin tissue sections (Figure 3A, panel i), semi-thin plastic sec-
tions (Figure 3A, panel ii), or epithelial cell adhesion molecule
(EPCAM) immunostained sections (Figure 3B). Similarly, we
found morphologic changes in developing AEC2s in vivo in
SftpcI73T knockin mice, which do not survive birth (Nureki
et al., 2018). For example, we examined E18.5 lungs from these
mice and found they displayed arrested lung morphogenesis in
late sacculation and complete obliteration of primordial saccules
by clumps of HA-tagged pro-SFTPCI73T expressing cells (Fig-
ure 3C). Most importantly, analysis of the SPC2 donor lung
explant also revealed distal lung morphological changes with
areas of hyperplastic or clumped AEC2s that differed from
normal lung tissue control sections (Figure 3D; arrowheads),
further validating the observations made in vitro in the human
iAEC2s. Furthermore, analysis of the same patient lung sections
for the AEC1 marker RAGE revealed paucity of AEC1s (Fig-
ure S2A), similar to findings described in SftpcI73T knockin
mice (Nureki et al., 2018), suggesting disruption of AEC2/AEC1
cell homeostasis as a result of AEC2 dysfunction.
To screen for potential morphological differences in lamellar
bodies between mutant and corrected iAEC2s, we employed to-
luidine blue-stained plastic sections (Figure 3A, panel ii) as well
as transmission electron microscopy (TEM) (Figure 3E). We
observed small inclusions reminiscent of lamellar bodies, pre-
sent intracellularly in both corrected and mutant iAEC2s (Fig-
ure 3A panel ii; arrowheads) and extracellularly in the lumens of
corrected alveolospheres, possibly reflecting lamellar body
exocytosis (Figure 3A panel ii; ellipse), in keeping with our prior
publication characterizing surfactant secretion from iAEC2s
(Jacob et al., 2017). TEM confirmed these inclusions to be
lamellar bodies (Figure 3E), with no appreciable difference in
lamellar body ultrastructure observed between mutant and cor-
rected cells, despite the clumped growth pattern of mutant
iAEC2s. The altered morphological appearance of mutant
iAEC2s included a lack of the characteristic apical-facing
‘‘bucket’’-like shape of EPCAM immunostaining observed in cor-
rected iAEC2s (Figure 3B), suggesting potential apical-basal po-
larity defects in mutant cells. To directly assess polarity we
immunostained for the apical epithelial markers MUC1, phos-
phorylated ezrin/radixin/moesin (p-ERM), and CRB3 and the ad-
herens junction protein E-cadherin/CDH1 (Figure S2B). We
found that while in corrected iAEC2s MUC1, p-ERM, and
CRB3 localized to the luminal apical cell surface and E-cadherin
localized on the basal-lateral membrane, mutant iAEC2s ex-
hibited diffuse distribution of these markers across all surfaces
(Figure S2B), indicating disrupted apical-basal polarity.
To examine the effects of the SFTPCI73T mutation on human
surfactant protein processing, we analyzed protein extracts
from normal primary adult AEC2s in comparison to corrected
versus mutant iAEC2s. In humans, SFTPC protein is produced
(E) Histograms show higher proliferation rates in SFTPCtdT/WT compared to SFTPCI73T/tdT iAEC2s, measured by flow cytometry as the frequency of
SFTPCtdTomato+ cells that incorporate EdU.
(F) Representative confocal immunofluorescence microscopy of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s stained for activated caspase 3 (green) and DNA
(Hoechst, blue) shows absence of significant apoptosis. Scale bars, 50 mm.
(A and C–E) Mean ± SD is shown; n = 3 experimental replicates of independent wells of a differentiation.
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exclusively by AEC2s as a 21 kDa pro-protein that undergoes
four endoproteolytic cleavages to generate the mature 3.7 kDa
form for secretion (Figure 3F) (Beers et al., 1994; Beers and Mu-
lugeta, 2005; Brasch et al., 2002). Complete biosynthesis re-
quires directed anterograde trafficking from Golgi to lamellar
bodies, and only cells expressing these organelles are capable
of fully processing SFTPC to its mature form. Western blot anal-
ysis revealed that mutant iAEC2s accumulated both significant
amounts of misprocessed pro-SFTPC forms (Figure 3G, arrow-
head) as well as increased amounts of incompletely processed
intermediate forms (Figure 3G, right arrow), suggesting aberrant
post-Golgi targeting coupled with inefficient posttranslational
processing of the SFTPCI73T primary translation product and in-
termediates (Figure 3G, right bracket and arrow, respectively). In
contrast, corrected iAEC2s demonstrated restoration of a
normal pro-SFTPC processing pattern (Figure 3G, left bracket
and arrow) and production of mature 3.7 kDa SFTPC (Figure 3G,
right panel). Despite inefficient turnover of mutant pro-
SFTPCI73T, production of mature 3.7 kDa SFTPC was also
observed in mutant iAEC2s but accumulated to a greater degree
than in corrected iAEC2s, suggesting its turnover is also ineffi-
cient (Figure 3G, right panel). By comparison, mutant iAEC2s
demonstrated intact SFTPB protein processing generating
roughly similar amounts ofmature 8 kDa SFTPB (Figure 3H), sug-
gesting that differences in mutant SFTPC posttranslational pro-
cessing and turnover were likely not a result of a broader AEC2
trafficking dysfunction. In support of this, immunostaining re-
vealed normal pro-SFTPC intracellular localization to lamellar
bodies of corrected iAEC2s, observed as distinct cytoplasmic
puncta (Figure 3I, arrowheads), whereas in mutant iAEC2s,
pro-SFTPCwasmislocalized to the plasmamembrane (Figure 3I,
arrowhead). Mistrafficking of pro-SFTPC to the plasma mem-
brane was also demonstrated in vivo in sections of the SPC2
donor lung explant (Figures 3D and 3J). Similar to the normal
SFTPB processing profile, immunostaining revealed normal
intracellular localization of SFTPB in both mutant and corrected
iAEC2s in vitro (Figure 3I) as well as in the donor patient’s lung
tissue in vivo (Figure 3J). Misprocessing and mistrafficking of
pro-SFTPC was also validated in the SPC2 line biallelically ex-
pressing both the mutant and ‘‘footprint-free’’ corrected SFTPC
alleles (SFTPCI73T/WT) (Figures S1C andS1D) aswell as the SPC6
and SPC7 iPSC lines (Figure S1E).
Transcriptomic and proteomic profiling of SFTPCI73T
iAEC2s and their gene-corrected counterparts
identifies differential regulation of the lysosomal/
autophagy pathway
We next sought to identify the downstream consequences of
pro-SFTPCmisprocessing andmistrafficking by profiling mutant
and corrected iAEC2s by single-cell RNA sequencing (scRNA-
seq), bulk RNA sequencing, and proteomic analyses. Transcrip-
tomes profiled at single-cell resolution were more similar at early
time points (day 30) after the initial onset of SFTPC expression
but diverged over time at later time points (day 113 or day 114)
in two repeated experiments (Figures 4A and S3A; day 114
scRNA-seq experiment includes all live cells irrespective of
SFTPCtdTomato expression). For example, only 224 genes were
differentially expressed at day 30, whereas 1,107 genes were
differentially expressed by day 113 between mutant and cor-
rected iAEC2s (false discovery rate [FDR] <0.05) (Table S2).
Cell populations at each time point remained similarly pure in
terms of frequencies of expression of NKX2-1, SFTPB (Figures
4B, S3B, and S3C), SFTPC (Figures 4C, 4D, S3B, and S3C), as
well as the AEC2 program (Figures 4D, S3B, and S3C), based
on quantification of expression of our previously defined
8-gene AEC2 differentiation and 5-gene AEC2 maturation
benchmarks established using primary adult AEC2s (Hurley
et al., 2020). Importantly, the cells did not detectably assume
alternative lung or non-lung fates based on little to no expression
of airway (SCGB1A1, FOXJ1, TP63, and KRT5) (Figure 4B) (Hur-
ley et al., 2020), endothelial (CDH5) (Figure 4B), hematopoietic
(PTPRC) (Figure 4B), or non-lung endodermal (CDX2, AFP, and
ALB) (Figure S3C) transcripts.
Although both mutant and corrected iAEC2s captured for
scRNA-seq analysis expressed similar frequencies of the AEC2
program (Figure S3C), mutant cells exhibited significantly higher
expression levels of AEC2 marker genes (Figures 4B–4E) and
less proliferation (significantly lowerMKI67 expression and lower
frequencies of cells in G2/S/M cell-cycle phases) (Figures 4B,
4D, and S3B). For example, 11 out of the top 50 differentially
Figure 3. SFTPCI73T/tdT iAEC2s demonstrate distinct cellular morphology and misprocess and mistraffick pro-SFTPC similarly to in vivo
SFTPCI73T-expressing AEC2s
(A) Representative H&E staining of formalin fixed and paraffin embedded sections (i, scale bars, 50 mm) and toluidine blue staining of plastic sections (ii) of
SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s. Arrowheads indicate lamellar body-like inclusions; eclipse indicates intraluminal inclusions.
(B) Representative confocal immunofluorescencemicroscopy of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s for EPCAM (green) and DNA (Hoechst, blue). Scale bars,
10 mm.
(C) Representative staining of E18.5 CFlp-SFTPCI73T/I73T and CFlp-SFTPCWT/WT embryos for HA-tagged SFTPC. Scale bars, 70 mm.
(D) Representative confocal immunofluorescence microscopy of distal sections of SPC2 donor and healthy donor lung explants stained for EPCAM (red), pro-
SFTPC (green), and DNA (Hoechst, blue). Scale bars, 10 mm.
(E) Representative TEM images of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s depicting lamellar bodies. Scale bars, 1 mm.
(F) Schematic representing the cellular compartments in which pro-SFTPC processing into mature SFTPC occurs. ER, endoplasmic reticulum; MVB, multi-
vesicular body; LB, lamellar body.
(G and H) Representative western blots of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2 lysates at the indicated time points were compared to freshly isolated primary
human AEC2s lysates for pro-SFTPC (NPRO-SFTPC) (G, left panel), mature SFTPC (G, right panel), and mature SFTPB (H) with b actin as a loading control.
(I) Representative confocal immunofluorescence microscopy of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s for pro-SFTPC (red; with zoom), EPCAM (green; with
zoom), SFTPB (red), and DNA (Hoechst, blue). Scale bars, 10 mm.
(J) Representative confocal immunofluorescence microscopy of distal sections of SPC2 donor and healthy donor lung explants for pro-SFTPC (green), EPCAM
(red), SFTPB (green), and DNA (Hoechst, blue). Scale bars, 10 mm.












Figure 4. Transcriptomic and proteomic/phosphoproteomic analyses identify candidate disease-associated pathways
(A) Clustering of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2 scRNA-seq transcriptomes at two time points (days (d)30 and 113 of differentiation) using Uniform
Manifold Approximation Projection (UMAP).
(legend continued on next page)




upregulated genes in mutant iAEC2s in the day 113 scRNA-seq
were composed of transcripts encoding surfactants, lamellar
body-related, and other AEC2-marker genes (PGC, SFTPB,
SLPI, NAPSA, SLC34A2, LPCAT1, SFTPA1, CEACAM6,
MUC1, SFTPC, and TDTOMATO) (Figure 4C). We validated
these findings by real-time qPCR quantitation (Figure S3D) as
well as in independent experiments analyzed by bulk RNA-seq
at 2 time points, day 114 and day 131 of differentiation, again
finding AEC2 gene markers comprised 14% of the top 50 most
upregulated genes in mutant iAEC2s (Figure 4E).
By global proteomic analysis performed on the same day as
scRNA-seq, SFTPC was the most enriched protein overall in
mutant versus corrected iAEC2s (ranked by FDR) (Figure 4F),
consistent with our SFTPC western blot and immunostaining
findings. Additional AEC2 proteins were also over-represented
in the top 50most upregulated proteins in mutant cells, including
SFTPB, SFTPA1, SLPI, and PGC, suggesting that both tran-
scripts and proteins encoding multiple surfactants and other
AEC2 markers were in the top most upregulated in mutant
iAEC2s. Proteomic analysis also validated the less proliferative
state of mutant iAEC2s as MKI67 protein was enriched in
corrected cells, whereas cell-cycle inhibitors CDKN1C and
CDKN2C were upregulated in mutant cells (Figure 4F). Analysis
of SPC2 donor’s lung explant sections also revealed a higher
in vivo pro-SFTPC immunostaining intensity compared to control
distal lung (Figure 4G), suggesting accumulation of mutant pro-
SFTPC in the patient’s AEC2s.
Having established that mutant iAEC2s display a less prolifer-
ative and more mature AEC2 phenotype than corrected cells
with marked accumulation of SFTPC protein, we next sought
to determine signaling pathways or biological processes that
might differ in mutant cells. The autophagy-related protein
ATG2B, essential for lysosomal formation, was in the top 10
most upregulated proteins (ranked by logFC) inmutant cells (Fig-
ure 4F) and gene set analysis of GO, KEGG, and HALLMARK
terms using both proteomic, scRNA-seq, and bulk RNA-seq an-
alyses all revealed significant upregulation of lysosomal and
autophagy-related terms in mutant cells (Figures 4H and S3E).
A systems-based approach integrating transcriptomic, proteo-
mic, and phosphoproteomic analyses revealed a high degree
of concordant regulation with protein secretion processes being
perturbed across all datasets consistent with the build-up
of secretory proteins evident on western blots and immunos-
tains. In addition, altered apical junctional processes, glycolysis,
STAT3 signaling, MTOR signaling, and inflammatory signaling
via nuclear factor kB (NF-kB) implied additional broad perturba-
tions were present across a wide variety of epithelial, metabolic,
and inflammatory cellular processes in mutant iAEC2s, whereas
proliferation pathways (E2F and MYC targets) were downregu-
lated (Figure 4I). Given that mutant and corrected iAEC2s are
(with the exemption of the SFTPCI73Tmutation) otherwise genet-
ically identical, the data above suggest that expression ofmutant
SFTPC drives a transcriptomic program that markedly alters the
iAEC2 phenotype and includes alterations in protein expression,
quality control, and intracellular signaling.
SFTPCI73T iAEC2s display autophagy perturbations
Given the potential effect of the SFTPCI73T mutation on auto-
phagy suggested by our bioinformatic analyses (Figure 4H, I),
we employed a variety of independent static and dynamic
approaches to evaluate the autophagy pathway in iAEC2s
(Figure 5A). We first assessed the intracellular levels of microtu-
bule-associated protein 1 light chain 3 (LC3), a marker of
autophagosome formation (Klionsky et al., 2016). Western blot
analysis showed elevated LC3, suggesting an increased auto-
phagosomal mass in mutant compared to corrected iAEC2s
(Figure 5B). To distinguish between enhanced autophagosome
formation versus reduced degradation, we examined the levels
of p62 (SQSTM1). P62 through direct interaction with LC3, facil-
itates transfer of polyubiquitinated proteins to the completed au-
tophagosome where it is degraded along with its cargo, thus
serving as a marker of autophagic degradation. Mutant iAEC2s
demonstrated significant accumulation of p62, compared to cor-
rected iAEC2s, consistent with a reduction in autophagosome
degradation (Figure 5B). To further delineate if the accumulation
of LC3 in mutant iAEC2s was the result of only reduced autopha-
gosome degradation or a concomitant induction in autophago-
some formation, we performed autophagic flux studies. We first
examined the response to the mTOR inhibitor/autophagy acti-
vator torin. When compared to their corrected counterparts,
mutant iAEC2s demonstrated significantly lower LC3 turnover
following treatment with torin for 18 h (55.2% ± 9.4% versus
(B) Average expression levels and frequencies (purple dots) for select genes profiled by scRNA-seq in SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s. Comparison is
made to a publicly available adult primary distal lung dataset (Habermann et al., 2020), and genes are selected to indicate AEC2, AEC1, airway, endothelial,
epithelial, leukocyte, or proliferation programs.
(C) Heatmap of top 50 upregulated and top 50 downregulated genes comparing d113 SFTPCtdT/WT versus d113 SFTPCI73T/tdT iAEC2s by scRNA-seq (ranked by
average log fold-change, FDR <0.05; row-normalized expression Z scores). A subset of differentially expressed genes is highlighted with large font.
(D) Violin plots showing normalized expression for indicated genes or cell cycle phase in d30 and d113 SFTPCtdT/WT versus SFTPCI73T/tdT iAEC2s by scRNA-seq.
(E) Heatmap of the 50 upregulated and top 50 downregulated genes in d114 SFTPCtdT/WT versus d114 SFTPCI73T/tdT iAEC2s by bulk RNA seq (ranked by FDR,
FDR <0.05; row-normalized expression Z scores). AEC2-marker genes are highlighted with large font.
(F) Volcano plots indicating differential protein expression in d113 SFTPCtdT/WT versus d113 SFTPCI73T/tdT iAEC2s by mass spectrometry.
(G) Representative confocal immunofluorescence microscopy of distal sections of SPC2 donor and healthy donor lung explants stained for pro-SFTPC (green)
andDNA (Hoechst, blue) shows an altered cellular localization pattern and a higher pro-SFTPC fluorescence intensity in the patient’s AEC2s, quantified by relative
fluorescence units (RFU). Scale bars, 10 mm (mean ± SD; n = 35 individual SFTPC-positive cells treated as experimental replicates).
(H) Top 10 upregulated pathways in d113 SFTPCI73T/tdT versus d113 SFTPCtdT/WT iAEC2s based on global proteomic analysis.
(I) Integrated gene set enrichment analyses based on scRNA-seq transcriptomic, proteomic, and phosphoproteomic analyses in d113 SFTPCI73T/tdT versus d113
SFTPCtdT/WT iAEC2s with an FDR <0.1 in at least 2 out of 3 datasets. NES, normalized enrichment score; gene ratio, ratio of enriched genes for a given pathway to
the total number of genes in the pathway. The last column represents the number of datasets (out of 3) with an FDR <0.05.
**p < 0.01, ***p < 0.001, and ****p < 0.0001 by unpaired, two-tailed Student’s t test for all panels.












Figure 5. Autophagy perturbations in SFTPCI73T iAEC2s
(A) Schematic illustrating the autophagy pathway. Key proteins involved in the pathway (p62/SQSTM1 and LC3) and the mechanisms of action of bafilomycin A1
and torin are depicted.
(legend continued on next page)




26.7% ± 0.3% reduction over baseline, p = 0.05) (Figure 5C). We
then examined the effect of bafilomycin A1 (BafA1), a vacuolar-
type H+-ATPase (V-ATPase) inhibitor, which inhibits autophago-
some degradation via both neutralizing the lysosomal pH and by
blocking the fusion of autophagosomes with lysosomes (Klion-
sky et al., 2016; Yamamoto et al., 1998). Treatment with BafA1
50 nM resulted in earlier accumulation and higher amounts of
LC3 in mutant compared to corrected iAEC2s suggesting
increased autophagosome formation (Figure 5D). The auto-
phagy perturbations observed in mutant (SFTPCI73T/tdT) iAEC2s
were further validated in the SPC2 line biallelically expressing
both mutant and corrected SFTPC alleles (SFTPCI73T/WT), as evi-
denced by the accumulation of both LC3 and p62 in mutant
iAEC2s (Figure S1C). Together, these results suggest a concom-
itant upregulation of autophagosome formation (flux) in mutant
iAEC2s as well as a late block in autophagy (autophagosome
turnover) consistent with our previous studies in heterologous
cell lines stably expressing SFTPCI73T and in vivo in our SftpcI73T
mouse model (Hawkins et al., 2015; Nureki et al., 2018).
To further corroborate the observed changes in biochemical
markers of autophagy, we next utilized advanced imaging tech-
niques to assess autophagosome dynamics in individual
iAEC2s. We first transduced mutant and corrected iAEC2s with
a lentiviral construct constitutively expressing GFP fused to
LC3 (LC3:GFP) (Twig et al., 2008) to visualize and quantitate au-
tophagosome numbers, which are represented by cytosolic
GFP-positive punctae. Consistent with the biochemical profile
(Figure 5B), under steady-state conditions, we found more auto-
phagosomes in mutant versus corrected iAEC2s (Figure 5E). The
fusion between autophagosomes and lysosomes promotes the
degradation of both LC3 and GFP facilitated by low autophago-
lysosome pH that can be blocked by treatment with BafA1 (Ni
et al., 2011). Treatment with BafA1 50 nM for 1 h enhanced
both GFP fluorescence and the numbers of GFP-positive punc-
tae in mutant iAEC2s compared to similarly treated corrected
iAEC2s consistent with increased autophagic flux (Figure 5E).
Similar observations were made in the SPC6 iPSC line where
increased numbers of GFP-positive punctae were identified at
both steady-state conditions and following treatment with
BafA1 (50 nM for 1 h), compared to corrected (SFTPCtdT/WT)
iAEC2s (data not shown). Morphologically, the SPC6 iAEC2s
lacked lumens and formed ball-like structures (data not shown)
similar to SFTPCI73T/tdT iAEC2s (Figures 3A and 3B). The
changes in autophagosome dynamics in mutant iAEC2s were
further confirmed using ultrastructural analysis by TEM where
double membrane intracellular vacuoles characteristic of auto-
phagosomes were easily visualized in mutant iAEC2s, whereas
these structures remained sparse in any of the corrected iAEC2s
(Figure 5F).
We further compared our iAEC2 in vitro model to in vivo
changes that arise soon after induction of the Sftpc mutation in
tamoxifen-inducible SftpcI73T knockin mice. Fourteen days after
in vivo administration of tamoxifen or vehicle to adult mice, we
isolated AEC2s to profile the proliferation state and autophagy
pathway. In contrast to iAEC2s after prolonged culture periods,
mouse mutant AEC2s were more proliferative compared to
wild-type (WT) AEC2s (Figure 5G), possibly attributed to the
in vivo setting with alternative lineages present. Nonetheless,
mouse mutant AEC2s demonstrated similar pro-SFTPC mispro-
cessing and autophagy perturbations with accumulation of both
LC3 and p62 (Figure 5H), suggesting that the differences in pro-
liferation states between mutant and corrected AEC2s did not
account for the observed autophagic changes.
Because fusion with acidic lysosomes is required for autopha-
gosome degradation, we considered the possibility that failure of
lysosomes to properly acidify might explain the block in auto-
phagy observed in mutant iAEC2s. We therefore stained mutant
and corrected iAEC2s with LysoTracker green (a basic dye that
stains acidic vesicular organelles) (Figure 5I) and found that
mutant iAEC2s contained more acidic organelles compared to
corrected cells (Figure 5J). To better assess the iAEC2 lysosomal
pH, we used Lysosensor yellow/blue-dextran (Figure S4), a pH-
sensitive fluorescent probe targeting the lysosomes with high
specificity (Wolfe et al., 2013). Quantitation of probe fluores-
cence revealed that lysosomes of mutant iAEC2s maintained a
lower intraluminal pH when compared to those of corrected
iAEC2s (Figure 5K). Together, these data indicate that mutant
iAEC2s exhibit an accelerated autophagy flux (autophagosome
(B) Representative western blot of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2 lysates for p62 and LC3 with GAPDH and b actin as loading controls with densitometric
quantification (mean ± SD; n = 11 for LC3 and n = 7 for p62 independent experiments).
(C)Western blots of cell lysates for LC3 and b actin from autophagic flux studies using SFTPCtdT/WT or SFTPCI73T/tdT iAEC2s treatedwith either torin (5 mM) for 4, 8,
or 18 h or bafilomycin A1 (BafA1) (50 or 100 nM) for 18 h or vehicle (DMSO) for 4 or 18 h (blots shown are representative of n = 2 independent experiments).
(D) A repeat autophagic flux study, as in (C) but using BafA1 (50 nM) for 1, 2, 4, and 18 h or vehicle (DMSO) for 18 h (representative of n = 2 independent
experiments).
(E) SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s transduced with a lentiviral LC3:GFP fusion protein and exposed to BafA1 (50 nM) to quantify autophagosomes and
autophagolysosomes. Scale bar, 10 mm (representative confocal fluorescence microscopy images of n = 3 experimental replicates of independent wells of a
differentiation).
(F) Representative TEM image of SFTPCI73T/tdT iAEC2s shows a double-membrane autophagosome (inset, arrowheads). Scale bar, 1 mm.
(G) Real-time qPCR showing fold change in gene expression compared toWT in primarymouse SftpcI73TAEC2s (mean ±SEM; n = 6 for SftpcI73T and n = 5 for WT
mice).
(H) Representative western blots of primarymouseWT and SftpcI73TAEC2 lysates for pro-SFTPC (NPRO), LC3, and p62with b actin as a loading control (see also
Figure 3G) (n = 3 WT and SftpcI73T mice).
(I) Representative live-cell confocal fluorescence microscopy of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s stained with LysoTracker green. Scale bars, 10 mm.
(J) Quantification of acidic organelles expressed as percentage of covered cell area (mean ± SD; n = 11–14 independent alveolospheres treated as experimental
replicates).
(K) Quantification of lysosomal pH based on Lysosensor yellow/blue-dextran ratio (mean ± SD; n = 2 independent experiments with 20–30 cells analyzed per
experiment; see also Figure S4).
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, by unpaired, two-tailed Student’s t test for all panels.













Figure 6. SFTPCI73T-expressing AEC2s demonstrate metabolic reprogramming
(A) Representative live-cell confocal fluorescence microscopy of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s stained with MitoTracker green. Scale bars,
10 mm.
(legend continued on next page)




and autophagolysosome formation) without impairment of vacu-
olar acidification, suggesting that the enhanced production of
mutant SFTPCI73T has saturated the autophagic capacity of
mutant iAEC2s without altering lysosomal pH.
Mutant human iAEC2s in vitro and mouse AEC2s in vivo
demonstrate metabolic reprogramming
Recognizing that changes inmetabolic pathways (i.e., glycolysis)
were among the top differentially upregulated pathways in
mutant iAEC2s in our integrated analysis (Figure 4I) coupled
with our prior work showing that expression of SFTPCI73T
could also alter steady-state mitochondrial mass and
membrane potential (Hawkins et al., 2015; Nureki et al., 2018),
directed us to investigate changes in cellular bioenergetics of
mutant iAEC2s. Mitochondrial morphology and mass were
assessed using quantitative imaging of MitoTracker dye
staining. Distinct mitochondrial morphologies were observed in
mutant versus corrected iAEC2s. Although the mitochondria in
corrected cells were more elongated forming a network extend-
ing from the basal-lateral to the apical cell surface, in mutant
cells, mitochondria demonstrated a rounded, fragmented
morphology (Figure 6A). Mutant iAEC2s also demonstrated
higher mitochondrial mass (Figure 6B) with accumulation of
larger (Figure 6C) but more fragmented mitochondria quantified
by the aspect ratio (ratio of long over short diameter) (Figure 6D),
changes previously described in primary AEC2s from patients
with IPF and aged mice (Bueno et al., 2015). The higher mito-
chondrial mass in mutant iAEC2s was confirmed by the higher
levels of mitochondrial protein TOM20, which appeared to be
time-dependent with enhanced accumulation as the cells aged
in culture (Figure 6E).
To investigate whether the changes in mitochondrial
morphology between mutant and corrected iAEC2s were asso-
ciated with changes in mitochondrial function, we performed
respirometry experiments at different time points: earlier time
points close to our prior transcriptomic/proteomic analyses (dif-
ferentiation days 128 and 153) and later time points (differentia-
tion days 175, 213, and 291). At the earlier time points, therewere
no significant differences betweenmutant and corrected iAEC2s
in terms of their basal oxygen consumption rate (OCR), maximal
uncoupled mitochondrial respiration (assessed after the admin-
istration of FCCP), and spare respiratory capacity (Figures 6F
and 6G). Similar to oxidative phosphorylation, no differences
were observed in glycolysis between mutant and corrected
iAEC2s, as measured by the extracellular acidification rate
(ECAR) either at steady-state or following treatment with the
ATP synthase inhibitor oligomycin (Figure 6H). However, at later
time points, which correspond to further aged iAEC2s, mutant
cells demonstrated a significant reduction in maximal uncoupled
mitochondrial respiration and spare respiratory capacity (Figures
6I and 6J). Conversely, mutant iAEC2s at later time points
demonstrated a higher ECAR (Figure 6K) suggestive of a meta-
bolic switch toward glycolytic metabolism. Becausemobilization
of lipid stores is required not only for energy utilization but also to
sustain the expansion of the surface area of the mitochondrial
membranes and autophagosomes, we assessed the lipid con-
tent of mutant and corrected iAEC2s. We found significantly
lower levels of stored triglycerides in mutant iAEC2s, as as-
sessed by BODIPY493/503 dye (Figure 6L).
To provide in vivo validation of our in vitro findings suggesting
metabolic reprogramming of mutant iAEC2s from oxidative
phosphorylation to glycolysis and to uncouple these changes
from the in vitro differences in proliferation rates betweenmutant
and corrected iAEC2s, we performed additional experiments us-
ing the same tamoxifen-inducible SftpcI73T knockin mouse
model. AEC2s were isolated 14 days following in vivo tamoxifen
or vehicle administration and subjected to respirometry experi-
ments. As shown above (Figure 5G), in this in vivomodel mutant
AEC2s are more proliferative compared to WT cells. Similar to
our in vitro model findings, we found a reduction in maximal un-
coupledmitochondrial respiration and spare capacity (Figure 6M)
as well as increased ECAR (Figure 6N) in the SftpcI73T mutant
(B–D) Quantitative analyses of morphometric data from fluorescence images (mean ± SD; n = 24 SFTPCtdT/WT and n = 18 SFTPCI73T/tdT independent alveolo-
spheres treated as experimental replicates).
(B) Increased mitochondrial mass in SFTPCI73T/tdT iAEC2s, quantified as the percentage of cell area covered by mitochondria.
(C) Increased mitochondrial size in SFTPCI73T/tdT iAEC2s.
(D) SFTPCI73T/tdT iAEC2 mitochondria are more fragmented, assessed by the aspect ratio.
(E) Representative western blot of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2 lysates for TOM20with b actin as loading control with densitometric quantification (mean
± SD; n = 4 [days 128, 176, 223, 223] SFTPCtdT/WT and n = 3 [days 128, 223, 223] SFTPCI73T/tdT independent experiments).
(F) Early time point OCR was measured under basal conditions followed by addition of oligomycin, FCCP, and antimycin A (Ant A), as indicated.
(G) SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s demonstrate no significant differences in proton leak, maximal respiration, and spare capacity measured as percent
change over basal respiration (mean ± SEM; n = 2 independent experiments).
(H) Early time point ECAR under basal conditions and following addition of oligomycin.
(I) Late time point OCR.
(J) SFTPCI73T/tdT iAEC2s demonstrate significantly lower maximal respiration and spare respiratory capacity (mean ± SEM; n = 3 independent experiments)
measured as percent change over basal respiration.
(K) Late time point reveals a significantly higher ECAR in SFTPCI73T/tdT iAEC2s (mean ± SD; n = 3 independent experiments).
(L) Representative live-cell confocal fluorescence microscopy of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s stained with BODIPY 493/503 dye with quantitative
analyses. Scale bars, 10 mm (mean ± SD; n = 10 SFTPCtdT/WT and n = 7 SFTPCI73T/tdT independent alveolospheres treated as experimental replicates).
(M) OCR measured under basal conditions and following addition of oligomycin, FCCP, and Ant A, as indicated (mean ± SD; n = 7 SftpcI73T and n = 5 WT mice).
(N) ECARmeasured under basal conditions in WT and SftpcI73Tmouse AEC2s (mean ± SEM; n = 5WTmice and n = 7 SftpcI73T). OCR, oxygen consumption rate;
ECAR, extracellular acidification rate.
(G and J) Depict super plots: small shapes represent replicate values within each experiment and large shapes represent the average of each independent
experiment, tdT/WT and I73T/tdT are color-matched between experiments. *p < 0.05 and ****p < 0.0001 by unpaired, two-tailed Student’s t test for all panels
except (M) where a mixed-effects model with Bonferroni’s correction was used.










Figure 7. SFTPCI73T/tdT iAEC2s display activation of the NF-kB pathway and are more susceptible to hydroxychloroquine treatment
(A) Unsupervised hierarchical clustered heatmap of differentially expressed proteins (FDR <0.05) in the depicted GO biological process gene set (row normalized
z-score); a subset of differentially expressed proteins is highlighted with large font.
(B) Schematic of NF-kB-luc-GFP lentiviral construct. LTR, lentiviral long terminal repeats; RRE, rev responsive element; CPPT, central polypurine tract; WPRE,
Woodchuck hepatitis virus post-transcriptional regulatory element; DU3, deleted U3 region for in vivo inactivation of the viral LTR promoter; J, Psi lentiviral
packaging sequence; GFP, green fluorescence protein.
(C) Representative live-cell imaging of lentivirally transduced SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s (bright-field/tdTomato/GFP overlay). Scale bars, 500 mm.
(D) Sort gates used to purify transduced (GFP+) SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s.
(E) Bioluminescence quantification shows increased luciferase activity in SFTPCI73T/tdT versus SFTPCtdT/WT iAEC2s. *p < 0.05, **p < 0.01, ***p < 0.001 by
unpaired, two-tailed Student’s t test for all panels.
(F) Luminex analysis of supernatants collected from SFTPCI73T/tdT and SFTPCtdT/WT iAEC2s for the NF-kB target proteins GM-CSF, CXCL5, and MMP-1.
*p < 0.05, **p < 0.01, ***p < 0.001 by unpaired, two-tailed Student’s t test for all panels.
(G) SFTPCtdT/WT or SFTPCI73T/tdT iAEC2s were treated with hydroxychloroquine (HCQ; 10 mM) or vehicle (ddH2O) for 18 h or 7 days. Lysates were subjected to
western blotting for LC3 with b actin as loading control. Densitometric quantification is shown. See also Figure S5. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired,
two-tailed Student’s t test for all panels.
(legend continued on next page)




AEC2s when compared toWT AEC2s. Together, these data sug-
gest that SFTPC mutant AEC2s demonstrate metabolic reprog-
ramming from oxidative phosphorylation to glycolysis, a process
that appears to be time-dependent.
SFTPCI73T iAEC2s elicit an inflammatory response
The proteomic analysis revealed upregulation of the NF-kB
pathway in SFTPCI73T mutant iAEC2s compared to their cor-
rected counterparts (Figure 7A). Because autophagy inhibition
has been shown to lead to activation of the NF-kB pathway via
upregulation of p62 (Hill et al., 2019), we sought to further vali-
date the proteomic findings. We utilized a lentiviral vector
(lenti-NF-kB-luc-GFP) (Figure 7B) that we previously engineered
to enable independent simultaneous tracking of transduced
(GFP+) cells by flow cytometry and real-time assessment of
NF-kB activation levels quantified by a luciferase reporter whose
expression is regulated by a minimal promoter element pre-
ceded by consensus binding sites for the canonical NF-kB
p50–p65 heterodimer transcription factor complex (Wilson
et al., 2013). Mutant and corrected iAEC2s were infected with
the lentiviral vector (MOI 20: Figure 7C), allowed to expand in cul-
ture, and transduced (GFP+) SFTPCtdTomato+ mutant and cor-
rected iAEC2s were then sorted and analyzed for luciferase
expression (Figure 7D). Mutant iAEC2s demonstrated increased
bioluminescence compared to corrected iAEC2s, suggesting
increased canonical NF-kB activity in mutant iAEC2s (Figure 7E).
Furthermore, mutant iAEC2s secreted higher levels of the NF-kB
target proteins GM-CSF, CXCL5, and MMP-1 quantified by Lu-
minex analysis of supernatants, compared to corrected iAEC2s
(Figure 7F). Taken together, these findings suggest mutant
iAEC2s are an important proinflammatory hub with resultant
secretion of inflammatory mediators via activation of the NF-kB
pathway.
Treatment of SFTPCI73T iAEC2s with
hydroxychloroquine results in aggravation of autophagy
perturbations and metabolic reprogramming
To apply our iPSC-derivedmodel system as a preclinical disease
model for drug testing, in a proof-of-principle experiment we as-
sessed the effect of hydroxychloroquine (HCQ) on SFTPCI73T-
expressing iAEC2s. HCQ is a medication commonly used either
alone or in combination with corticosteroids in pediatric patients
with genetic disorders of surfactant dysfunction affecting AEC2s
(including SFTPCI73T) and resulting in chILD. The use of HCQ in
this patient population is based primarily on evidence from
case reports or small cohort studies with variable results (Braun
et al., 2015; Klay et al., 2018; Kröner et al., 2015). HCQ is a lyso-
somotropic medication that accumulates in lysosomes inhibiting
lysosomal activity and autophagy (Mauthe et al., 2018;
Schrezenmeier and Dörner, 2020) raising the possibility it may
aggravate the autophagic block already present in SFTPCI73T-
expressing iAEC2s. Indeed, treatment of mutant iAEC2s with
HCQ (10 mM) for 7 days resulted in increased accumulation of
LC3 in HCQ-treated compared to untreated iAEC2s (Figures
7G and S5A). Notably, treatment of corrected iAEC2s with
HCQ under the same conditions did not result in significant
changes of total LC3 suggesting that mutant iAEC2s are more
sensitive to HCQ’s lysosomotropic effect. Long-term treatment
of mutant iAEC2s with HCQ (10 mM) resulted in further reduction
of the already diminished self-renewal capacity of these cells
(Figure 7H), whereas bothmutant and corrected iAEC2s retained
expression of the SFTPCtdTomato reporter (Figure S5B). Further-
more, mutant iAEC2s treated with HCQ for 7 days demonstrated
a significant reduction in OCR/ECAR ratio assessed after the
administration of oligomycin and FCCP, compared to untreated
iAEC2s (Figure S5C). This suggests a shift toward glycolysis, re-
vealed after pharmacological manipulation of energy supply and
demand and reminiscent of the observations made earlier for
aged mutant iAEC2s (Figure 6). Similar to LC3 levels, HCQ treat-
ment had no effect on the OCR/ECAR ratio in corrected iAEC2s
(Figure S5C).
DISCUSSION
Our results suggest that patient-specific iAEC2s can serve as a
human preclinical disease model, revealing key components of
the epithelial-intrinsic pathophysiology of human AEC2
dysfunction and providing a platform to test therapeutics. Pa-
tient-derived iAEC2s expressing mutant SFTPCI73T in this
model exhibit misprocessed and mistrafficked pro-SFTPC pro-
tein, recapitulating the mistrafficking occurring in vivo in the
donor’s AEC2s. The accumulation of misprocessed pro-
SFTPC, as a result of mutant SFTPCI73T expressed from the
endogenous human locus in AEC2-like cells, extends similar
observations previously made based on forced overexpression
of mutant protein in heterologous cell lines (Brasch et al., 2004;
Galetskiy et al., 2008; Hawkins et al., 2015; Stewart et al., 2012),
profiles of patient bronchoalveolar lavage samples (Brasch
et al., 2004), and recently in an in vivo mouse model (Nureki
et al., 2018).
The iAEC2 platform also offers the ability to temporally model
both the early changes coinciding with accumulation of mutant
SFTPC forms and the resulting downstream sequence of events
leading to acquisition of a dysfunctional AEC2 phenotype. Multi-
omic profiling of syngeneically controlled mutant versus cor-
rected iAEC2s identified similarities at an early time point but
more distinct phenotypes emerged with culture expansion sug-
gesting a time-dependent phenotype. This time course is in
agreement with the SftpcI73T mouse, where an age-dependent
lung-diseased phenotype emerged simultaneously with the
gradual accumulation of mutant pro-SFTPC forms (Nureki
et al., 2018).
Among the many cellular programs disrupted in the iAEC2
model, our findings suggest an early perturbation in autophagy.
(H) Graph showing yield in cell number per input SFTPCtdT/WT or SFTPCI73T/tdT iAEC2 with or without treatment with HCQ (10 mM). ****p < 0.0001 across all groups
by one-way ANOVA; p < 0.001 for d10, p < 0.01 for d20, p < 0.0001 for d31, and p < 0.05 for d44 for corrected versus mutant iAEC2s by unpaired, two-tailed
Student’s t test.
Mean ± SD is shown; n = 3 (E and F) or n = 2 (G) experimental replicates of independent wells of a differentiation or n = 3 (H) biological replicates of independent
differentiations.




First, unbiased signaling pathway analysis identified the lyso-
somal/autophagy pathway as being differentially upregulated
in mutant iAEC2s. We validated these observations by a variety
of independent static and dynamic approaches (Figure 5) that
documented induction of autophagosome formation (flux) and
defined a late block in autophagy at the level of autophagosome
turnover, evidenced by accumulation of LC3 and p62 and incom-
plete response to torin in mutant iAEC2s. Importantly, we vali-
dated these observations in vivo in primary mouse SftpcI73T
AEC2s that are not hypo-proliferative, suggesting that the accu-
mulation of misprocessed and mistrafficked pro-SFTPC was
responsible for the observed phenotype rather than the prolifer-
ative differences between mutant and corrected iAEC2s. A dys-
regulated autophagic response has been shown in IPF lungs
(Araya et al., 2013; Hill et al., 2019; Patel et al., 2012) and has
been postulated to lead to epithelial cell senescence and myofi-
broblast differentiation (Araya et al., 2013; Hill et al., 2019).
Although it remains unclear mechanistically how SFTPC
buildup/misprocessing leads to autophagy perturbations, we
speculate that it is likely related to failure of lysosomal fusion
because lysosomal acidification appears intact in mutant
iAEC2s. The resultant proteostasis perturbations and alterations
in cellular quality control resulted in diminished progenitor
potential as evidenced by reduced self-renewal capacity.
Furthermore, the paucity of AEC1s in the donor’s lung explant
(Figure S2A), similar to findings described in our SftpcI73T
knockin mice (Nureki et al., 2018), point to disruption of normal
AEC2/AEC1 homeostasis as a result of AEC2 dysfunction. Inef-
fectual AEC2-to-AEC1 differentiation and emergence of a transi-
tional cell state have been described in IPF (Jiang et al., 2020;
Riemondy et al., 2019). In addition, selective AEC2 ablation (Bar-
kauskas et al., 2013; Garcia et al., 2016; Sisson et al., 2010) or
AEC2 senescence induction via conditional deletion of Sin3a
(Yao et al., 2020) in mice have resulted in progressive pulmonary
fibrosis, either spontaneously or after bleomycin exposure.
Therefore, our results agree with the growing body of literature
suggesting that dysfunctional AEC2s could initiate the fibrotic
cascade.
Because autophagy plays an important role in selective degra-
dation of dysfunctional mitochondria, this may explain our
observation that mutant iAEC2s displaying an autophagy pheno-
type accumulated dysmorphic and dysfunctional mitochondria
in a time-dependent manner, changes previously described in
primary AEC2s from patients with IPF and aged mice (Bueno
et al., 2015). We further validated the mitochondrial dysfunction
and metabolic reprogramming observed in mutant iAEC2s in
primary mouse SftpcI73T AEC2s. Assessing the bioenergetics
of human AEC2s has not been previously possible given the
challenges in culturing primary AEC2s.
In addition to detailed alterations in cell quality control and
metabolism, our data also provide a plausible explanation of
how a dysfunctional AEC2 signals to surrounding cells to initiate
inflammatory and profibrotic cascades, because the NF-kB
pathway was found to be differentially upregulated in mutant
compared to corrected iAEC2s. Furthermore, higher levels of
the NF-kB target proteins GM-CSF, CXCL5, and MMP-1 were
identified in the supernatants of mutant compared to corrected
iAEC2s. Importantly, GM-CSF is a strong chemoattractant for
profibrotic Ly6chi monocytes that have been implicated in the
pathogenesis of lung fibrosis (Misharin et al., 2017; Venosa
et al., 2019).
Finally, in a proof-of-principle experiment, we tested the appli-
cation of our model system as a preclinical human disease drug
testing platform by assessing the effect of HCQ on SFTPCI73T-
expressing cells. Treatment of mutant iAEC2s resulted in
aggravation of the observed autophagy perturbations, further
reduction of the already diminished self-renewal capacity, and
metabolic reprogramming toward glycolysis. Taken together,
the findings from our epithelial-only model system suggest that
treatment with HCQ could be detrimental to patients carrying
the SFTPCI73T variant, although a pleiotropic effect resulting
from HCQ’s effect on immune cells or beneficial effects on other
cell types in vivo cannot be excluded.
Prior reports (Jacob et al., 2017; Korogi et al., 2019; Strikou-
dis et al., 2019) have provided proof-of-concept that ESC- or
iPSC-derived lung epithelia carrying certain mutations
could model some aspects of either adult or pediatric ILD,
such as inflammatory activation. We believe the current study
adds to these prior reports by addressing some of the many
mechanisms associated with a cell autonomous, epithelial-
intrinsic toxic gain-of-function in purified patient-specific
iAEC2s, including detailed profiles of the perturbations in
protein trafficking, autophagy, mitochondrial morphology, and
function.
In summary, our epithelial-only patient-specific iAEC2 model
system not only recapitulates key observations made previously
in heterologous cell lines and in vivo mouse models (as well as
in vivo in the patient from whom the iPSCs were generated) but
also provides new insights into the potential role of AEC2s in
the inception of pulmonary fibrosis and serves as a preclinical
platform to test therapeutics.
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Antibodies
Rabbit polyclonal to activated caspase 3 Sigma Aldrich Cat# C8487; RRID:AB_476884
Mouse monoclonal to b actin Sigma Aldrich Cat# A1978; RRID:AB_476692
Mouse monoclonal to CD26, PE conjugated (clone BA5b) BioLegend Cat# 302705; RRID:AB_314289
Mouse monoclonal to CD47, PerCP-Cy5.5 conjugated
(clone CC2C6)
BioLegend Cat# 323110; RRID:AB_940461
Rabbit polyclonal to CRB3 Szymaniak et al., 2015 N/A
Mouse IgG1 isotype, PE conjugated BioLegend Cat# 400113; RRID:AB_326435
Mouse IgG1 isotype, PerCP–Cy5.5 conjugated BioLegend Cat# 400149; RRID:AB_893680
Mouse monoclonal to E-Cadherin/CDH1 BD Biosciences Cat# 610181; RRID:AB_397580
Mouse monoclonal to EPCAM Santa Cruz Cat# Sc-73491; RRID:AB_1122569
Mouse monoclonal to GAPDH Chemicon Cat# MAB374; RRID:AB_2107445
Rabbit monoclonal to NKX2-1 (clone EP15847) Abcam Cat# ab76013; RRID:AB_1310784
Rabbit monoclonal to Phospho-Ezrin/Radixin/Moesin (p-ERM) Cell Signaling Cat# 3726; RRID:AB_10560513
Mouse monoclonal to pro-SFTPC Santa Cruz Cat# sc-518029
Rabbit polyclonal to pro-SFTPC Seven Hills Cat# WRAB-9337; RRID:AB_2335890
Rabbit polyclonal to mature SFTPC Seven Hills Cat# WRAB-76694
Rabbit polyclonal anti-NPRO-SFTPC Beers et al., 1994 N/A
Rabbit polyclonal anti-mature SFTPB (PT3) Beers et al., 1992 N/A
Rabbit monoclonal to MUC1 Abcam Cat# Ab218998
Rabbit polyclonal to HA tag Abcam Cat# Ab20084; RRID:AB_445319
Mouse monoclonal to RAGE Abcam Cat# Ab54741; RRID:AB_2242462
Rabbit polyclonal to LC3B Cell Signaling Cat# 2775; RRID:AB_915950
Mouse monoclonal to SQSTM1/p62 Abcam Cat# Ab56416; RRID:AB_945626
Mouse monoclonal to CPM Wako Cat# 014-27501; RRID:AB_2801482
Mouse monoclonal to SLC34A2 Yin et al., 2008 N/A
AffiniPure Donkey Anti-Rabbit IgG (H+L), AlexaFluor
488 conjugated
Jackson ImmunoResearch Cat# 711-545-152; RRID:AB_2313584
AffiniPure Donkey Anti-Rabbit IgG (H+L), AlexaFluor
647 conjugated
Jackson ImmunoResearch Cat# 711-605-152; RRID:AB_2492288
AffiniPure Donkey Anti-Mouse IgG (H+L), AlexaFluor
488 conjugated
Jackson ImmunoResearch Cat# 715-545-150; RRID:AB_2340846
AffiniPure Donkey Anti-Mouse IgG (H+L), AlexaFluor
647 conjugated
Jackson ImmunoResearch Cat# 715-605-150; RRID:AB_2340862
AffiniPure Goat Anti-Mouse IgG (H+L), AlexaFluor
488 conjugated
Jackson ImmunoResearch Cat# 115-545-062; RRID:AB_2338845
AffiniPure Goat Anti-Rabbit IgG (H+L), AlexaFluor
488 conjugated
Jackson ImmunoResearch Cat# 111-545-144; RRID:AB_2338052
AffiniPure Goat Anti-Mouse IgG (H+L), AlexaFluor
594 conjugated
Jackson ImmunoResearch Cat# 115-585-146; RRID:AB_2338881
AffiniPure Goat Anti-Rabbit IgG (H+L), AlexaFluor
594 conjugated
Jackson ImmunoResearch Cat# 111-585-144; RRID:AB_2307325
Goat Anti-Mouse IgG (H+L), HRP conjugated BioRad Cat# 0300-0108P; RRID:AB_808614
Goat Anti-Rabbit IgG (H+L), HRP conjugated BioRad Cat# 5196-2504; RRID:AB_619908
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Chemicals, peptides and recombinant proteins
Human embryonic stem cell (hESC)- qualified (2D) Matrigel Corning Cat# 354277
Growth Factor Reduced (3D) Matrigel Corning Cat# 356231
SB431542 Tocris Cat# 1614
Dorsomorphin Stemgent Cat# 04-0024
CHIR99021 (CHIR) Tocris Cat# 4423
Recombinant human FGF10 R&D Systems Cat# 345-FG-025
Recombinant Human Keratinocyte Growth Factor (KGF) R&D Systems Cat# 251-KG-010
Recombinant Human BMP4 (rhBMP4) R&D Systems Cat# 314-BP
Retinoic acid Sigma Aldrich Cat# R2625
Y-27632 dihydrochloride Tocris Cat# 1254
Ascorbic Acid Sigma Aldrich Cat# A4544
1-Thioglycerol (MTG) Sigma Aldrich Cat# M6145
BSA 7.5% Stock Thermo Fisher Scientific Cat# 15260037
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (EDTA) Sigma Aldrich Cat# E7889
N-(2-Hydroxyethyl)piperazine-N’-(2- ethanesulfonic acid)
Solution (HEPES)
Sigma Aldrich Cat# H0887
Dexamethasone Sigma Aldrich Cat# D4902
8-bromoadenosine 30,50-cyclic monophosphate sodium
salt (cAMP)
Sigma Aldrich Cat# B7880
3-Isobutyl-1-methylxanthine (IBMX) Sigma Aldrich Cat# I5879
Puromycin Dihydrochloride Thermo Fisher Scientific Cat# A1113802
Geneticin Sulfate Life Technologies Cat# 11811-023
0.05% trypsin-EDTA Invitrogen Cat# 25300-120
Defined Fetal Bovine Serum Thermo Fisher Scientific Cat# NC0652331
Dimethyl Sulfoxide (DMSO) Sigma Aldrich Cat# D2650
Calcein blue Life Technologies Cat# C1429
Hoechst 33342 Thermo Fisher Scientific Cat#H3570
DAPI, FluoroPure grade Invitrogen D21490
ProLong Diamond Antifade Mountant Invitrogen Cat# P36965
LysoTracker Green DND-26 Thermo Fisher Scientific Cat# L7526
MitoTracker Green FM Thermo Fisher Scientific Cat# M7514
BODIPY-493/503 Thermo Fisher Scientific Cat# D3922
LysoSensor Yellow/Blue Dextran Thermo Fisher Scientific Cat# L22460
Dispase II Thermo Fisher Scientific Cat# 17105-041
Glutaraldehyde Ladd Research Cat# 20100
Osmium Tetroxide Polysciences Cat# 0223D
Uranyl Acetate Electron Microscopy Sciences Cat# 22400
EMbed 812 Electron Microscopy Sciences Cat# 14120
Paraformaldehyde Electron Microscopy Sciences Cat# 19208
Oligomycin Millipore Cat# 495455
FCCP Sigma Aldrich Cat# C2920
Antimycin A Sigma Aldrich Cat# A8674
Bafilomycin A1 Sigma Aldrich Cat# B1793
Torin Tocris Cat# 4247
Critical commercial assays
RNeasy Mini Kit QIAGEN Cat# 74104
QIAzol Lysis Reagent QIAGEN QIAGEN Cat# 79306
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TaqMan Fast Universal PCR Master Mix (2X) Thermo Fisher Cat# 4364103
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems Cat# 4368814
EZ-TAL TALE Assembly Kit System Bioscience Cat# GE120A-1
Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit Thermo Fisher Scientific Cat# C10424
Lipofectamine LTX Kit Thermo Fisher Scientific Cat# 15338100
P3 Primary Cell 4D-NucleofectorO X Kit S Lonza Cat# V4XP-3032
Magnetic Luminex Performance Assay Human
HighSensitivity
R&D Systems Cat# LXSAHM-31
Deposited data
Single cell transcriptomic profiling of patient-specific
pluripotent stem cell-derived alveolar epithelial type
2 cells expressing the SFTPCI73T variant and their
gene-edited corrected counterparts
This paper GEO (GSE160801)
Proteomic and phosphoproteomic profiling of SFTPCI73T
expressing patient-specific pluripotent stem cell-derived
alveolar epithelial type 2 cells and their gene-edited
corrected counterparts.
This paper PRIDE: PXD022334
Experimental models: Cell lines
Human: SFTPCI73T/WT donor iPSC line (SPC2) This paper http://stemcellbank.bu.edu/
Catalog/Item/Home








Human: Donor iPSC line targeted with
SFTPCtdTomato (SPC2-ST-B2; SFTPCtdT/WT)
Kotton Lab; Hurley et al., 2020 http://stemcellbank.bu.edu/
Catalog/Item/Home
Oligonucleotides
See Table S3 This paper N/A
Recombinant DNA
EF1a-TALEN_HD; SFTPC recognition sequence of
right TALEN 50-TCA CCG GCG GGC TCT CCA TC-30.
Kotton Lab; Jacob et al., 2017 http://www.kottonlab.com
EF1a-TALEN_NN; SFTPC recognition sequence of
left TALEN: 5’-TAG CAC CTG CAG CAA GAT GG-30.
Kotton Lab; Jacob et al., 2017 http://www.kottonlab.com
p1303-DV-SFTPC-tdTomato Kotton Lab; Jacob et al., 2017 http://www.kottonlab.com
pHAGE2 EF1a-Cre-IRES-NeoR-W Kotton Lab; Jacob et al., 2017 http://www.kottonlab.com
pHAGE2-Cre-IRES-PuroR Kotton Lab; Somers et al., 2010 Addgene #30205
Software and algorithms
FlowJo version 10.5.3 Becton, Dickinson & Company https://www.flowjo.com/
ImageJ National Institutes of Health https://imagej.nih.gov/ij/
CellProfiler v2.0 Broad Institute https://cellprofiler.org
Prism GraphPad https://www.graphpad.com/
Original code This paper https://github.com/CReM-
BU/Alysandratos_iAEC2s
Other
StemDiff Definitive Endoderm Kit StemCell Technologies Cat# 05110
mTeSR1 StemCell Technologies Cat# 05850
Glutamax Life Technologies Cat# 35050-061
Gentle Cell Dissociation Reagent StemCell Technologies Cat# 07174
Seahorse XF Base Medium Minimal DMEM Agilent Technologies Cat# 103193-100
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Further information and requests for reagents may be directed to, and will be fulfilled by, the Lead Contact, Darrell Kotton
(dkotton@bu.edu).
Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agree-
ment. Pluripotent stem cell lines generated in this study are available from the CReM iPSC Repository at Boston University and Bos-
ton Medical Center and can be found at https://www.bu.edu:443/dbin/stemcells/.
Data and code availability
The scRNA-seq data reported in this publication have been deposited in NCBI’s Gene Expression Omnibus (GEO; accession number
GSE160801). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the Prote-
omics Identifications (PRIDE) partner repository with the dataset identifier PRIDE: PXD022334. All original code has been deposited
at GitHub and is publicly available as of the date of publication. DOIs are listed in the key resources table. Any additional information
required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
iPSC line generation and maintenance
All experiments involving the differentiation of human iPSC lines were performed with the approval of the Institutional Review Board
of Boston University (protocol H33122). The Human Research Protection Office of Washington University School of Medicine,
St. Louis, MO, approved procurement of dermal fibroblasts for reprogramming with written informed consent. The iPSC line
SPC2 was derived by reprogramming these fibroblasts from a patient with childhood interstitial lung disease (chILD) that
progressed to end stage lung disease with pulmonary fibrosis requiring lung transplantation (clinical details provided in the sup-
plemental data). Gene sequencing documented a heterozygous SFTPC pathogenic variant in the non-BRICHOS domain,
c.218 T > C (p.I73T) (Figure 1). Reprogramming to generate iPSCs was performed using the excisable, floxed lentiviral STEMCCA
vector followed by excision of the single integrated lentiviral copy via transient Cre-recombinase exposure and confirmation of suc-
cessful STEMCCA excision (SPC2-18Cr1 clone; SFTPCI73T/WT) prior to directed differentiation, as previously published (Somers
et al., 2010). We have previously published partial characterization of the corrected SPC2 line (SPC2-ST-B2), without disease
modeling, including stability of the AEC2 phenotype in the corrected iAEC2s derived from this clone after prolonged cell culture
expansion (Hurley et al., 2020). The SPC6 and SPC7 iPSC lines were generated by reprogramming peripheral blood mononuclear
cells (PBMCs) from two individuals with the SFTPCI73T variant and clinically phenotyped chILD (clinical details provided in the sup-
plemental data) using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Invitrogen, Thermofisher, Cat# A16517) according to the
manufacturer’s instructions, with detailed methods available for free download from the CReM’s protocols page at https://www.
bumc.bu.edu/stemcells. The Institutional Review Board of Boston University approved procurement of these PBMCs and reprog-
ramming into iPSCs with written informed consent.
All iPSC lines (SPC2-ST-B2, SPC2-ST-C11, SPC2-18Cr1, SPC2-CorrC1, SPC6, and SPC7) used in this study demonstrated a
normal karyotype (46XY or 46XX) when analyzed byG-banding and/or array Comparative Genomic Hybridization (aCGH) both before
and after gene-editing (Cell LineGenetics) (Figure S6A). Pluripotencywas confirmed by staining for pluripotencymarkers (Figure S6B)
as previously described (Somers et al., 2010). Culture conditions used for maintenance and editing of undifferentiated iPSCs were as
follows: for Transcription activator-like effector nucleases (TALEN) targeting, iPSC lines weremaintained onmitomycin C-inactivated
mouse embryonic fibroblasts (MEFs) in human iPSC media (WiCell feeder dependent protocol). For CRISPR targeting and prior to
directed differentiation, all iPSC lines were maintained in feeder-free conditions, on growth factor reduced Matrigel (Corning) in
6-well tissue culture dishes (Corning), in mTeSR1 media (StemCell Technologies) using gentle cell dissociation reagent (GCDR)
Continued
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Hank’s Buffered Saline Solution
(HBSS; no calcium, no magnesium, no phenol red)
GIBCO Cat# 14175095
Ham’s F12 Medium Cellgro Cat# 10-080-CV
Iscove’s Modified Dulbecco’s Medium (IMDM) Thermo Fisher Scientific Cat# 12440053
N2 Supplement Invitrogen Cat# 17502-048
B27 Supplement Invitrogen Cat# 15260-037
Primocin Invitrogen Cat# NC9141851




for passaging. Further details of iPSC derivation, characterization, and culture are available for free download at https://www.bu.
edu:443/dbin/stemcells/protocols.php.
Generation of gene-edited syngeneic iPSC lines
To generate gene-edited corrected syngeneic iPSC lines two approaches were undertaken. In the first approach, we used TALENs to
insert a tdTomato fluorescent reporter at the translation initiation (ATG) site of the endogenous SFTPC locus of the parental SPC2
iPSC line, as previously described (Jacob et al., 2017). All TALENs and donor template plasmid maps and sequences are available
at www.kottonlab.com. The SFTPC TALEN recognition sequences are: left TALEN 50-TAG CAC CTG CAG CAA GAT GG-30 and right
TALEN 50-TCACCGGCGGGCTCTCCA TC-30. Between the two binding sites is a 22 bp spacer (ATG TGGGCAGCAAAGAGGTCC
T). TALENs were constructed using EZ-TAL TALE Assembly Kit (System Bioscience), according to manufacturer’s instructions, and
the resulting SFTPC TALENs encoding plasmids were named EF1a-TALEN_NN (SPC left) and EF1a-TALEN_HD (SPC right),
respectively.
To deliver the donor template to the SFTPC locus, we generated a donor vector (p1303 DV-SFTPC-tdTomato) containing the
tdTomato coding sequence and a floxed PGK promoter-driven puromycin resistance cassette, flanked by left and right arms of ho-
mology to the human endogenousSFTPC locus, as previously described (Jacob et al., 2017). The TALENs and donor vector plasmids
were co-transfected into the SPC2 iPSC line using a lipofectamine based transfection protocol. For this purpose, SPC2 iPSCs were
plated onto a mitomycin C-inactivated DR4 MEF feeder layer and cultured in human iPSC media (WiCell) in a 6-well plate. After the
cells reached 50% confluence, they were transfected with the two TALENs and tdTomato donor vector as follows: 3 mg of donor vec-
tor and 1.2 mg of each TALEN were added to 275 ml of IMDM and 4 ml of Plus reagent from the Lipofectamine LTX kit (Thermo Fisher
Scientific) and the mixture was incubated at room temperature for 5 minutes. 16 ml of lipofectamine LTX from the same kit was added
to another 275 ml of IMDM. 275 mL of the DNAmixture was added to 275 mL of the LTXmixture and incubated at room temperature for
30minutes. 550 ml of the total mixturewas added drop by drop to 1well of a 6-well plate. Five hours later, themediawas changed, and
48 hours later, 0.7 mg/ml puromycin (Thermo Fisher Scientific) was added to the media for 4 days to select antibiotic resistant col-
onies. After 10 days individual colonies were picked and screened for targeting using the following primer pairs: 50 GGG TGA GTG
AGC TGA TTC GAG 30, 50 TGA CCT CCT CGC CCT TGC TCA CCA TG 30. DNA sequencing using a primer binding in the genome
outside any regions included in targeting plasmids confirmed targeting into the endogenous SFTPC locus (50 GGG TGA GTG
AGC TGA TTC GAG 30). To confirm heterozygous targeting, colonies were screened for a remaining intact SFTPC allele using the
following primers: 50 CTA CGG ACA CAT ATA AGA CCC TGG TC 30, 50 CAA ATA GCC ACC ATT CGG ACA CTC 30. DNA sequencing
of the amplified portion of the intact SFTPC allele was performed using the following primer 50 TAT GGG GAT GGG TAC CAC TGG
CTG 30 to pick colonies of either corrected (SPC2-ST-B2 clone; SFTPCtdT/WT) or mutant (SPC2-ST-C11 clone; SFTPCI73T/tdT) iPSC
clones as the tdTomato cassette is followed by a stop/polyA cassette, preventing expression of the subsequent SFTPC coding
sequence from the targeted allele (Figure 1D).
Cre-mediated excision of the floxed puromycin resistance cassette was performed using a plasmid containing Cre-recombinase
and neomycin resistance (PHAGE2 EF1a-Cre-IRES-NeoR-W; www.kottonlab.com) using the same lipofectamine-based protocol
described above, with 4 days of 200 ng/ml geneticin-based (Life Tech) selection for clones that were transfected with Cre-containing
plasmid. Excision of the puromycin cassette was confirmed by PCR using the following primers: 50 ATG ACC GAG TAC AAG CCC
ACG 30, 50 TCA GGC ACC GGG CTT GC 30.
In the second approach, we employed the CRISRP/Cas9 gene editing technology to generate a gene-edited corrected iPSC line
that expressed two active SFTPC alleles (SPC2-CorrC1 clone; SFTPCWT/WT) as described below. Using the CRISPR/Cas9 technol-
ogywe targeted the region adjacent to the I73Tmutation (c.218 T >C (p.I73T)) in theSFTPC gene locus (Figure S1B) with a guide RNA
(specifically recognizing the I73Tmutation but not wild-type) that had the following sequence: 50 CAGGTTCTGGAGATGAGCAC 30.
gRNA sequences were cloned into the pD1321-AD plasmid backbone (DNA 2.0 ATUM) that contains a M-dasher-GFP sequence
fused to Cas9. Delivery of this plasmid to iPSCs enabled co-expression of Cas9, gRNA, and a GFP reporter. To accomplish foot-
print-free correction of the SFTPC variant, a short single stranded DNA oligo (sequence 50 GGT GGC TCC ATG CCC TTT CCC
CAG GTT CTG GAA ATG TCA ATT GGT GCG CCG GAA GCC CAG CAA CGC CTG GCC CTG AGT GAG 30) was used as a donor
template containing the wild-type SFTPC sequence. SPC2 cells maintained in feeder-free conditions in mTeSR1media were treated
with 10 mM Y-27632 (Tocris) for 3 hours, dissociated in GCDR (StemCell Technologies) for 10 minutes at 37C and counted using a
Luna-II Automated Cell Counter (Logos Biosystems, Annandale, VA). Approximately 5x106 cells were centrifuged at 200 g for
5 minutes, resuspended in a mixture containing P3 solution and supplement (P3 Primary Cell 4D-Nucleofector X Kit L, Lonza) as
well as 5 mg CRISPR/Cas9 plasmid and 5 mg oligo donor, and nucleofected using program code CB-150 in the 4D Nucleofector X
System (Lonza). Nucleofected cells were replated on 4 wells of a Matrigel-coated 6-well plate in mTeSR1 media, and 10 mM
Y-27632 was added for 24 hours. After 48 hours, cells were prepared for sorting. They were treated with 10 mMY-27632 for 3 hours,
dissociated into single cell suspension with GCDR for 10-15 minutes at 37C, centrifuged at 200 g for 5 minutes, resuspended in
mTeSR1media supplemented with 10 mMY-27632, and filtered through a 30 mm filter (Falcon). GFP+ cells were sorted into recovery
media (1 part mTeSR1 and 1 part conditioned mTeSR1 supplemented with 0.7ng/ml FGF2, plus 10 mMY-27632) using a high-speed
cell sorter (MoFlo Legacy, BeckmanCoulter). 1x104GFP+ sorted cells were plated into a 10 cm tissue culture treated dish pre-coated
with growth factor reducedMatrigel (Corning). Recovery media was changed every other day for the first 5 days, with 10 mMY-27632
added for the first 24 hours. After 5 days, mTeSR1 was used to feed the cells daily, and after 10 days, colonies that emerged were of




sufficient size for picking for clonal expansion and screening. Individual colonies were picked and screened for correction using the
following primers: 50 GTC GTG GTG ATT GTG GGA GCC CTG 30, 50 CTG GGC ATA CCC ACC TGC TGG TAG 30. DNA sequencing
using the following primer 50 TAT GGG GAT GGG TAC CAC TGG CTG 30 confirmed correction of the SFTPC variant, resulting in
generation of the SPC2-Corr line.
METHOD DETAILS
iPSC directed differentiation into alveolar epithelial type 2 cells (iAEC2s)
To generate iAEC2s, we performed PSC directed differentiation via definitive endoderm into NKX2-1 lung progenitors usingmethods
we have previously described (Hawkins et al., 2017; Jacob et al., 2017, 2019). In brief, cells maintained in mTeSR1media were differ-
entiated into definitive endoderm using the STEMdiff Definitive Endoderm Kit (StemCell Technologies) for 3 days (day 0-3) and after
the endoderm-induction stage, cells were dissociated with GCDR and passaged into 6-well dishes pre-coated with growth factor
reduced Matrigel in ‘‘DS/SB’’ anteriorization media, consisting of complete serum-free differentiation media (cSFDM) base as pre-
viously described (Jacob et al., 2017, 2019), supplemented with 2 mMDorsomorphin (‘‘DS’’; Stemgent) and 10 mMSB431542 (‘‘SB’’;
Tocris). For the first 24 hr after passaging, 10 mMY-27632 was added to the media. After anteriorization in ‘‘DS/SB’’ media for 3 days
(day 3-6), cells were cultured in ‘‘CBRa’’ lung progenitor-induction media until day 15 or 16, as we have previously published (Jacob
et al., 2017; Serra et al., 2017). ‘‘CBRa’’ media consists of cSFDM base supplemented with 3 mM CHIR99021 (Tocris), 10 ng/ml re-
combinant human BMP4 (rhBMP4, R&D Systems), and 100 nM retinoic acid (RA, Sigma). On day 15 or 16 of differentiation, live cells
were sorted on a high-speed cell sorter (MoFlo Legacy or MoFlo Astrios EQ) to isolate NKX2-1+ lung progenitors based on CD47hi/
CD26neg gating (Hawkins et al., 2017). Sorted lung progenitors were resuspended in undiluted growth factor reduced 3D Matrigel
(Corning) at a concentration of approximately 400 cells/ml and distal/alveolar differentiation of cells was performed in ‘‘CK+DCI’’
media, consisting of cSFDM base supplemented with 3 mMCHIR99021, 10 ng/mL rhKGF (CK), and 50 nM dexamethasone (Sigma),
0.1 mM 8-Bromoadenosine 30,50-cyclic monophosphate sodium salt (Sigma) and 0.1 mM 3-Isobutyl-1-methylxanthine (IBMX;
Sigma) (DCI). The resulting epithelial spheres were passaged without further sorting on approximate day 30 (day 28-37) of differen-
tiation and a brief period (4-5 days) of CHIR99021 withdrawal followed by one week of CHIR99021 addback was performed (Fig-
ure 1F) to achieve iAEC2 maturation, as previously shown (Jacob et al., 2017). After this 14-day period, SFTPCtdTomato+ cells were
purified by fluorescence activated cell sorting (FACS) and resuspended in undiluted growth factor reduced 3D Matrigel (Corning)
at a concentration of approximately 400 cells/ml in ‘‘CK+DCI’’ media to establish pure long-term iAEC2s cultures. iAEC2s were
then maintained through serial passaging as self-renewing monolayered epithelial spheres (‘‘alveolospheres’’) by plating in 3D
Matrigel (Corning) droplets at a density of 400 cells/ml with refeeding every other day with ‘‘CK+DCI’’ media, according to our pre-
viously published protocol (Jacob et al., 2019). iAEC2 culture quality and purity was monitored at each passage by flow cytometry,
with > 95% of cells expressing SFTPCtdTomato over time (Figure 2A).
Murine model of SftpcI73T
Tamoxifen inducible SftpcI73T mice were generated and induced following previously reported protocols (Katzen et al., 2019; Nureki
et al., 2018). Briefly, the SftpcI73T founder line, expressing a neomycin cassette, was crossed with a mouse line expressing an estro-
gen receptor (ER)-2 controlled Flp-O recombinase strain knocked into the Rosa26 locus (Jackson Laboratory, Bar Harbor, ME) to
generate the inducible-SftpcI73TFlp line. Adult homozygote SftpcI73TFlp mice received tamoxifen (260 or 360 mg/kg in corn oil, oral
gavage) at 12-14 weeks of age. AEC2 isolation was performed 14 days after tamoxifen induction.
Mouse AEC2 isolation
Mouse AEC2s were isolated as previously reported (Atochina-Vasserman et al., 2011). Briefly, perfused mouse lungs were digested
with dispase (BD Biosciences), mechanically dissociated, and treated with 25 mg/ml DNAase I (Sigma-Aldrich). Negative selection of
mesenchymal cells (fibroblasts) was done by differential adherence on plastic culture dishes. CD45-positive cells were removed by
negative selection using Dynabeads Untouched Mouse T Cells Kit (11413D) and Dynabeads Mouse DC Enrichment Kit (11429D;
Thermo Fisher Scientific).
Flow cytometry and Fluorescence Activated Cell Sorting (FACS)
Preparation of single cell suspensions of 3D Matrigel-embedded iAEC2s for flow cytometry and FACS was achieved by
incubation with 2 mg/ml dispase (Thermo Fisher Scientific) for 30-60 minutes at 37C and subsequent incubation with 0.05% trypsin
for 12-15 minutes at 37C, as previously described (Jacob et al., 2019). Cells were washed with media containing 10% fetal bovine
serum (FBS, Thermo Fisher Scientific). Harvested cells were centrifuged at 300 g for 5 minutes at 4C and resuspended in FACS
buffer containing Hank’s Balanced Salt Solution (Thermo Fisher Scientific), 2% FBS and 10 mM Y-27632 (Tocris) and stained with
calcein blue AM (Thermo Fisher Scientific) for dead cell exclusion during flow cytometry. Live cells were sorted on a high-speed
cell sorter (MoFlo Legacy or MoFlo Astrios EQ, Beckman Coulter, Pasadena, CA) at the Boston University Medical Center Flow
Cytometry Core Facility.
Immunostaining of cells in single cell suspension with antibodies against CD47 (Biolegend) and CD26 (Biolegend) and FACS gating
of the CD47hi/CD26neg population for purification of lung progenitors was performed as previously described (Hawkins et al., 2017;




Jacob et al., 2019). Purification of iAEC2s for the establishment of pure long-term iAEC2 cultures following iAEC2 maturation
(via CHIR99021 withdrawal and addback) in the iPSC lines that had not been targeted with any fluorochrome reporters was
achieved by staining for carboxypeptidase M (CPM) (SPC2-18Cr1 and SPC2-CorrC1) or SLC34A2 (SPC6 and SPC7) as
detailed in Jacob et al. (2019): single cell suspicions were stained on ice in FACS buffer using a primary mouse monoclonal antibody
against human CPM (1:200, FujifilmWako) or SLC34A2 (MX35 1:200, a generous gift of Dr. Gerd Ritter, Memorial Sloan Kettering) for
30 minutes and subsequently stained with secondary Alexa Fluor 647 conjugated antibody (1:500, Thermo Fisher Scientific) for
20 minutes.
Gating was based on isotype-stained controls or in the case of SFTPCtdTomato on non-lung endoderm outgrowths (day 15-16
sorted CD47lo cells). Flow cytometry staining was quantified using the Stratedigm S1000EXI and analyzed with FlowJo v10.6.2
(FlowJo, Tree Star Inc). Flow cytometry plots shown represent single cells after forward-scatter/side-scatter gating to remove debris
as we have previously detailed in Jacob et al. (2019).
Immunofluorescence microscopy
Images of cultured 3D Matrigel-embedded iPSC-derived epithelial spheres were taken on a Keyence BZ-X700 fluorescence micro-
scope (Osaka, Japan). Z stack images were processed using full focus image analysis using Keyence software.
For the analysis of lysosomal, mitochondrial, and lipid droplet morphology, alveolospheres were harvested by incubating with
2 mg/ml dispase (Thermo Fisher Scientific) for 30-60 minutes at 37C and then stained with Hoechst 33432 (1 mg/ml, Thermo Fisher
Scientific) and LysoTracker Green DND-26 (1 mM, Thermo Fisher Scientific), MitoTracker Green (200 nM, Thermo Fisher Scientific),
or BODIPY-493/503 (1 mg/ml, Thermo Fisher Scientific) respectively for 45 minutes in CK+DCI media at 37C and 5% CO2. After
2 washes with fresh media, alveolospheres were plated onto Greiner CELLview glass-bottom 4-compartment dishes (Greiner Bio-
One GmbH) in 3D Matrigel (Corning) and CK+DCI media. Alveolospheres were imaged using a Zeiss LSM 880 confocal microscope
(Carl Zeiss AG, Oberkochen) with Airyscan super resolution detector using a 40x or 63x oil objective. For all samples Hoechst fluores-
cence, green fluorescence (LysoTracker, MitoTracker, or BODIPY-493/503), as well as tdTomato fluorescence were recorded. For the
duration of the imaging session alveolospheres were kept on a temperature and CO2 controlled humidified stage at 37
C and 5%CO2.
For the analysis of lysosomal pH, alveolospheres were stained with LysoSensor Yellow/Blue Dextran (5 mg/ml, Thermo Fisher Sci-
entific) for 1 hour in CK+DCI media at 37C and 5% CO2. Subsequently, after 2 washes with fresh media alveolospheres were plated
onto Greiner CELLview glass-bottom 4-compartment dishes in 3DMatrigel and CK+DCI media. After a 24-hour chase period alveolo-
sphereswere imaged using a Zeiss LSM880using 2-photon excitation at 720 nmand a 40x oil objective. LysoSensor fluorescencewas
recorded as blue emission (401-461 nm) and yellow emission (511-550 nm). Additionally, tdTomato fluorescence was recorded using
561 nm laser excitation and 571-620 nm emission. For the duration of the imaging session alveolospheres were kept on a temperature
and CO2 controlled humidified stage at 37
C and 5% CO2. For the determination of pH standard curves, alveolospheres stained with
LysoSensor Yellow/Blue Dextranwere fixed in 4%paraformaldehyde for 20minutes. After 3 washeswith PBS (pH 7.4), alveolospheres
were equilibrated in MES buffers (pH range between 4.5 and 6.0). LysoSensor fluorescence was recorded as above.
For formalin fixation and paraffin embedding, alveolospheres were harvested by incubating with 2 mg/ml dispase (Thermo Fisher
Scientific) for 30-60 minutes at 37C, fixed with fresh 4% paraformaldehyde overnight at 4C, combined in low melting agarose
(SeaPrep) to form a pellet and then paraffin embedded. For immunocytochemistry, sections were rehydrated and antigen retrieval
was performed at 95C for 20 minutes in Dako Target Retrieval Solution (DAKO, S-1699). Sections were permeabilized with 0.5%
Triton X-100 (Sigma-Aldrich), blocked with 4% normal donkey serum (NDS) for 1 hour, and incubated in primary antibody in 0.5%
Triton X-100 and 4% NDS overnight at 4C. The staining was detected with secondary Alexa Fluor-conjugated anti-IgG antibodies
purchased from Jackson Immunoresearch (donkey anti-rabbit, goat anti-mouse, goat anti-rabbit at 1:400 to 1:500 dilution for 1 hour
at room temperature) or Bio-Rad (goat anti-mouse, goat anti-rabbit at 1:10,000 dilution for 1 hour at room temperature) (see Key
resources table), as previously described (Hawkins et al., 2015, 2017; Nureki et al., 2018). Nuclear counterstaining was performed
with Hoechst dye (1:500, Invitrogen) or DAPI (300 nM, Invitrogen). Coverslips with cells were mounted on glass slides using Prolong
Diamond Anti-Fade Mounting Reagent (Thermo Fisher Scientific) and imaged on an Olympus I-70 inverted fluorescent microscope
(Olympus, Melville, NY), captured with a Hamamatsu 12-bit coupled-charged camera (Hamamatsu, Japan), and processed using
Metamorph, Version 7.8.4.0 (Universal Imaging,West Chester, PA) or imaged using a Zeiss LSM880 confocal microscope (Carl Zeiss
AG, Oberkochen) and processed using ImageJ. Primary antibodies (see Key resources table) include: a polyclonal anti-pro-SFTPC
antibody (‘‘NPRO-SFTPC,’’ 1:200) raised against the Met [10]–Glu [23] domain of rat pro-SFTPC and polyclonal anti-SFTPB (‘‘PT3’’)
raised against bovine SFTPB both produced in rabbits in house and validated as previously published (Beers et al., 1992, 1994; Beers
and Lomax, 1995), as well as a rabbit polyclonal anti-CRB3 antibody (1:1000; Szymaniak et al., 2015). Other commercially obtained
antibodies include: anti-activated caspase 3 (rabbit polyclonal, 1:200, Sigma-Aldrich), anti-E-Cadherin (mouse monoclonal, 1:500,
BD Biosciences), anti-EPCAM (mouse monoclonal, 1:100, Santa Cruz), anti-HA (rabbit polyclonal, 1:40,000, Abcam), anti-p-ERM
(rabbit monoclonal, 1:1000, Cell Signaling), anti-pro-SFTPC (rabbit polyclonal, 1:500, Seven Hills and mouse monoclonal, 1:500,
Santa Cruz), anti-MUC1 (rabbit monoclonal, 1:100, Abcam), anti-RAGE (mouse monoclonal, 1:250, Abcam).
Cell proliferation analysis
To assess DNA replication as a method of proliferation analysis, 5-ethynyl-20-deoxyuridine (EdU) incorporation was evaluated using
the Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen). Corrected andmutant SFTPCtdTomato+ iAEC2s were plated at




a concentration of 400 cells/ml in 3D Matrigel in CK+DCI media as described above. Seven days after plating, EdU was added to the
cultures (n = 3 independent droplets) for 24 hours at a final concentration of 10 mM. The cells were then dissociated into single cell
suspension as described above, fixed, permeabilized, and stained with the Click-iT reaction mixture according to themanufacturer’s
instructions. The percentage of SFTPCtdTomato+ cells that incorporated EdU was determined by flow cytometry (Stratedigm).
Transmission electron microscopy
Intact alveolospheres were harvested by incubating with 2 mg/ml dispase (Thermo Fisher Scientific) for 30-60 minutes at 37C and
fixed for 3 hours total in 2.5% glutaraldehyde (Ladd Research) in 0.1% cacodylate buffer (pH 7.4) at room temperature as follows: an
equal volume of 5% glutaraldehyde/ 0.1 M cacodylate was added to Eppendorf tubes containing the alveolospheres in known
volume of CK+DCI media, fixed for 1.5 hours, and centrifuged gently (300 g for 1 minute) followed by the addition of fresh 2.5%
glutaraldehyde/ 0.1 M cacodylate for an additional 1.5 hours at room temperature. The samples were then washed 3 times in
0.1 M cacodylate, post-fixed in 1% Tannic Acid in cacodylate buffer for 5 minutes at room temperature, washed again 3 times in
cacodylate buffer, and post-fixed overnight in 1.5% osmium tetroxide (Polysciences) in 0.1 M cacodylate buffer in dark at 4C.
The samples were then washed 3-4 times in 0.05 M Na Maleate buffer (pH 5.2) and block stained in 1.5% Uranyl acetate (Electron
Microscopy Sciences, EMS) in 0.025 M Na Maleate buffer (pH 6.0). Next, the samples were dehydrated quickly through acetone on
ice, from 70% to 80% to 90%. The samples were then incubated 2 times in 100% acetone at room temperature for 10 minutes each,
and in propylene oxide at room temperature for 15 minutes each. Finally, the samples were changed into EMbed 812 (EMS), left for 2
hours at room temperature, changed into fresh Embed 812 and left overnight at room temperature, after which they were embedded
in fresh EMbed 812 and polymerized overnight at 60C. Plastic embedded samples were thin sectioned at 70 nm and grids were
stained in 4% aqueous Uranyl Acetate for 5 minutes at 60C followed by Lead Citrate for 10 minutes at room temperature. Electron
microscopy was performed on a Philips CM12 EM operated at 100kV, and images were recorded on a TVIPS F216 CMOS camera
with a pixel size of 0.85-3.80 nm per pixel.
Other staining
Toluidine blue staining was performed as follows: 0.5 mm sections (from EMbed plastic blocks) were collected, dried for 30 minutes
on a hot plate, and stained 30-60 s in 0.5% Toluidine blue + 0.5% Borax in dH20, rinsed in dH20, dried and coverslipped. For He-
matoxylin and Eosin (H&E) staining standard methods were used (AML Labs, Inc, Baltimore, MD).
Quantification of autophagic flux
To quantify autophagosomes, corrected (SFTPCtdT/WT) or mutant (SFTPCI73T/tdT) iAEC2s were transduced with an LC3:GFP encod-
ing lentivirus (Twig et al., 2008) at anMOI of 20 in CK+DCImedia containing polybrene (5mg/ml). iAEC2swere then replated in growth
factor reduced 3D Matrigel (Corning) at a concentration of approximately 400 cells/ml in CK+DCI media for expansion. Single cell
suspension of transduced iAEC2s was achieved by incubation with 2 mg/ml dispase (Thermo Fisher Scientific) for 30-60 minutes
at 37C and subsequent incubation with 0.05% trypsin for 12-15minutes at 37C, as previously described (Jacob et al., 2019). Trans-
duced iAEC2s were plated onto Greiner CELLview glass-bottom 4-compartment dishes (Greiner Bio-One GmbH) pre-coated with
growth factor reduced Matrigel (Corning) in CK+DCI media. After 3 days, iAEC2s were imaged at 37C and 5% CO2, using a Zeiss
LSM 710-Live Duo Scan confocal microscope (Carl Zeiss AG, Oberkochen) (488 nm excitation), and GFP+ punctate autophago-
somes were quantified by visual inspection in 40–50 cells per group before and after 1 hour of incubation with 50 nM bafilomycin
A1 (LC Laboratories). LC3 and p62 were further quantified by western blot as described below.
Western Blot Analysis
Alveolospheres were harvested by incubating with 2mg/ml dispase (Thermo Fisher Scientific) for 30-60minutes at 37C, treated with
lysis buffer (RIPA buffer and 1x Roche Complete Protease Inhibitor cocktail), and incubated on ice for 30minutes. Cellular debris was
cleared by centrifugation at 15,000 g for 20 minutes and supernatants were harvested. Protein concentration was measured using
Bio-Rad DC Protein Assay. 5-30 mg of lysates were resolved on pre-cast 12%Bis-Tris NuPAGE gels (Invitrogen), transferred to PVDF
membranes (Bio-Rad), and blotted with primary antibodies (see below and Key resources table) followed by species-specific sec-
ondary antibodies conjugated to IR dyes of either 680 or 800 nm wavelengths (Rockland) at a dilution of 1:10000, as previously
described (Hawkins et al., 2015; Maguire et al., 2012). Primary antibodies (see Key resources table) include: surfactant protein B
(PT3, a rabbit polyclonal antibody against bovine mature SFTPB; [Beers et al., 1992]; 1:5000), pro-SFTPC (NPRO-SFTPC, a rabbit
polyclonal antibody against theMet [10]–Glu [23] domain of rat proSFTPC; [Beers et al., 1994]; 1:3000), mature SFTPC (1:2500, Seven
Hills), LC3B (1:750-1:1000, Cell Signaling), SQSTM1/p62 (1:1000, Abcam), b-actin (1:10000, Sigma), and GAPDH (1:5000, Chemi-
con). Visualization was accomplished using the Odyssey Imaging System (LiCOR Biosciences).
Respirometry assays
Alveolospheres were harvested by incubating with 2 mg/ml dispase (Thermo Fisher Scientific) for 30-60 minutes at 37C, washed,
and resuspended in 150-300 ml of Seahorse XF Base Media Minimal DMEM (Agilent Technologies) containing 2.8 mM glucose and
0.1% FBS (pH 7.4). Organoids were seeded in an XF96e Seahorse plate as described (Assali et al., 2019; Taddeo et al., 2020). Briefly,
growth factor reduced Matrigel (1.5 ml/well; Corning) was first pipetted in the center measurement zone of each well. The organoid




suspension (5-10 ml) was deposited in theMatrigel-coatedmeasurement zone using a pipette. The plate was then incubated in a non-
-CO2 incubator for 3.5 minutes to let the Matrigel solidify. Next, 150 ml of pre-warmed Seahorse media was slowly added to each well
to avoid dislodging the organoids from theMatrigel. The plate containing the organoids was centrifuged at 500 g for 5minutes with no
brake and subsequently incubated in a non-CO2 incubator for 30-45 minutes prior to running the assay. Oxygen consumption
was determined as described (Assali et al., 2019; Taddeo et al., 2020). Port injections were as follows: port A, oligomycin (final
concentration 4.5 mM/l); port B, FCCP diluted in a mixture of 80% sodium pyruvate and 20% of 1:1 l-leucine/l-glutamine (final con-
centration 1 mM/l FCCP in 11.4 mM/l sodium pyruvate and 2.9 mM/l each of leucine/glutamine); and port C, antimycin A (final con-
centration 2.5 mM/l). Once the Seahorse assay was complete, the plate was kept for mitochondrial content determination. Protein
concentration was determined by BCA assay (Thermo Fisher Scientific).
Mitochondrial content determination
Mitochondrial content was assessed using MitoTracker Deep Red (MTDR) as described (Acin-Perez et al., 2020). Briefly, samples
(5 mg) were incubated in the presence of 500 nM MTDR for 10 minutes in PBS at 37C. The plate was centrifuged at 2000 g for
10minutes andmedia containingMTDRwas discarded using a pipette. Then, 100 ml of PBSwas added per well. MTDR fluorescence
was measured in a fluorescence plate reader (Tecan, Männedorf, Switzerland) with excitation of 625 nm and emission of 670 nm.
Mitochondrial content was referred as MTDR RFU/mg protein.
Quantification of NF-kB signaling
To track the kinetics of the NF-kB pathway in iAEC2s, we utilized a lentiviral vector (lenti-NF-kB-luc-GFP) we have previously pub-
lished (Wilson et al., 2013) that allows independent simultaneous tracking of transduced (GFP+) cells by flow cytometry and assess-
ment of NF-kB activation levels by luciferase expression. This dual transgenesis vector contains four tandem copies of the canonical
NF-kB p50/p65 heterodimer consensus binding sequence located upstream of the minimal TA promoter (TAp), the TATA box of the
herpes simplex virus thymidine kinase (HSV-TK) promoter. Located downstream of TAp is the firefly luciferase reporter coding
sequence, followed by a constitutively active mammalian ubiquitin C (UBC) promoter driving GFP expression (Figure 7B). Corrected
(SFTPCtdT/WT) or mutant (SFTPCI73T/tdT) iAEC2s were transduced with the lentiviral vector at an MOI of 20 in CK+DCI media contain-
ing polybrene (5 mg/ml). iAEC2s were then replated in growth factor reduced 3D Matrigel (Corning) at a concentration of approxi-
mately 400 cells/ml in CK+DCImedia. Thirteen days later, corrected andmutant iAEC2s (n = 3 independent droplets) were dissociated
into single cells and sorted for transduced (GFP+) SFTPCtdTomato+ cells which were subsequently resuspended in 75 ml FACS buffer
and plated in a 96-well flat bottom black polystyrene microplate (Corning). Cells were then processed according to the Dual-Glo
Luciferase Assay System Protocol (Promega). Firefly luminescence was measured using the Tecan Infinite M200 Pro Micro Plate
Reader (Tecan, Männedorf, Switzerland). NF-kB target protein levels were further quantified by Luminex analysis as described
below.
Luminex analysis
Supernatants of corrected and mutant iAEC2s (n = 3 independent wells) were filtered through 0.22 mm filters (Millipore SCGP00525)
and analyzed using a customized Magnetic Luminex Performance Assay Human HighSensitivity Cytokine Base Kit (R&D Systems,
Inc). Mean fluorescence intensity was measured to calculate final concentration in pg/ml using Bioplex200 and Bioplex Manager 5
software (Bio-Rad) and adjusted to cell number.
Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)
RNA was extracted by first lysing cells in Qiazol (QIAGEN) and subsequently using RNAeasy mini kit (QIAGEN) according to the
manufacturer’s protocol. Complementary DNA (cDNA) was generated by reverse transcription of 150 ng RNA from each sample using
MultiScribe Reverse Transcriptase (Applied Biosystems). RT-qPCR was performed using TaqMan Fast Universal PCR Master Mix
(Thermo Fisher Scientific) and TaqMan (Applied Biosystems) reagents. The cDNA was diluted 1:4 and 2 mL of cDNA were added to
each 20 mL (for Applied Biosystems StepOne 96-well System) or 12 mL (for Applied Biosystems QuantStudio7 384-well system) RT-
qPCR reaction. Eachsamplewas run in technical triplicates for 40cyclesofPCRandcycle threshold (Ct) valueswereaveragedbetween
triplicates for analysis. Relative gene expression, normalized to 18S control, was calculated as fold change in 18S-normalized gene
expression, compared tobaseline, using the2(-DDCt)method.Baselineexpression,definedas foldchange=1,wasset toundifferentiated
iPSC levels, or if undetected, a cycle number of 40 was assigned to allow fold change calculations. Adult human lung control RNA was
extracted from a healthy donor’s distal lung explant. Specifics of primers used are detailed in Key resources table and Table S3.
Isolation of Human Fetal Lung Epithelium
Week 21 human lung tissueswere obtained in theGuttentag laboratory under protocols originally reviewed by the Institutional Review
Board at the Children’s Hospital of Philadelphia and subsequently reviewed by Vanderbilt University. The cell stocks used in the
present studies were donated to the Kotton laboratory for the purpose of providing reference data for this project and their charac-
terization was previously published (Hawkins et al., 2017). ‘‘Uncultured naı̈ve lung epithelial cells’’ were isolated by the overnight
culture of lung explants in Waymouth media; a technique that generally yields 86 ± 2% epithelial cells with the remaining cells con-
sisting of fibroblasts with < 1% endothelial cells (Wade et al., 2006).




RNA sequencing and bioinformatic analyses
For bulk RNA sequencing (RNA-seq) comparing corrected (SFTPCtdT/WT) and mutant (SFTPCI73T/tdT) iAEC2s at two different time
points (day 114 and day 131), experimental triplicate (n = 3) samples of purified RNA extracts were harvested from each group of
samples as follows. Alveolospheres were harvested from 3D Matrigel by incubating with 2 mg/ml dispase (Thermo Fisher Scientific)
for 30-60 minutes at 37C, washed twice with PBS, and RNA was extracted using the Qiazol and miRNeasy mini kit (QIAGEN) ac-
cording to manufacturer’s instructions. Flow cytometry analysis confirmed that these samples consisted of R 95% SFTPCtdTomato+
cells. mRNAwas isolated from each sample usingmagnetic bead-based poly(A) selection, followed by synthesis of cDNA fragments.
The products were end-paired and PCR-amplified to create each final cDNA library. Sequencing of pooled libraries was done using a
NextSeq 500 (Illumina). The quality of the raw sequencing data was assessed using FastQC v.0.11.7. Sequence readswere aligned to
a combination of the human genome reference (GRCh38) and the tdTomato reporter sequence, using STAR v.2.5.2b (Dobin et al.,
2013). Counts per gene were summarized using the featureCounts function from the subread package v.1.6.2. The edgeR package
v.3.25.10 was used to import, organize, filter and normalize the data. Genes that were not expressed in at least one of the experi-
mental groups were filtered out (keeping only genes that had at least 10 reads in at least 3 libraries, that is, a worthwhile number
of samples as determined by the replicate number in the design matrix. The TMM method was used for normalization. Principal
Component Analysis (PCA) and Multidimensional Scaling (MDS) were used for exploratory analysis, to assess sample similarities
and potential batch effects. Subsequently, the limma package v3.39.19 (Law et al., 2016) with its voom method, namely, linear
modeling and empirical Bayes moderation was used to test differential expression (moderate t tests). P values were adjusted for
multiple testing using Benjamini-Hochberg correction (false discovery rate-adjusted p value; FDR). Differentially expressed genes
between the groups in each experiment were visualized using Glimma v 1.11.1, and FDR < 0.05 was set as the threshold for deter-
mining significant differential gene expression. Gene set analysis was performed with Hallmark, KEGG, and GO Biological Process
gene sets using the Camera package (Wu and Smyth, 2012).
For single-cell RNA sequencing (scRNA-seq) comparing corrected (SFTPCtdT/WT) and mutant (SFTPCI73T/tdT) iAEC2s at two
different time points (day 30 and day 113), cells were dissociated for sorting as described previously. Cells were sorted as described
previously for viable (calcein blue+) SFTPCtdTomato+ cells and resuspended in FACS buffer at a concentration of 800-1000 cells/ml. For
the scRNA-seq experiment comparing corrected and mutant iAEC2s on day 114 (Figure S3), all live cells (calcein blue+) irrespective
of SFTPCtdTomato expression were included. Single cells were captured for sequencing library preparation using a 10X Chromium
(10X Genomics, Pleasanton, CA) instrument. scRNA-seq libraries were prepared according to the Single Cell 30 v3 Reagent Kits
User Guide (10X Genomics). Cellular suspensions were loaded on a Chromium Controller instrument (10X Genomics) to generate
single-cell Gel Bead-In-Emulsions (GEMs). Reverse transcription (GEM-RT) was performed in a Veriti 96-well thermal cycler (Thermo
Fisher Scientific). After RT, GEMswere harvested and the cDNAs were amplified and cleaned with SPRIselect Reagent Kit (Beckman
Coulter). Indexed sequencing libraries were constructed using the Chromium Single-Cell 30 Library Kit (10X Genomics) for enzymatic
fragmentation, end-repair, A-tailing, adaptor ligation, ligation cleanup, sample index PCR, and PCR cleanup. The barcoded
sequencing libraries were quantified by quantitative PCR using the KAPA Library Quantification Kit (KAPA Biosystems, Wilmington,
MA). Sequencing libraries were loaded on a NextSeq500 (Illumina) with a custom sequencing setting (26bp for Read 1 and 98bp for
Read 2), to obtain a sequencing depth of 50K reads/cell. Fastq files were generated using bcl2fastq v.2.2 and Cellranger v.3.0.2.
The sequence files were mapped to the human genome reference (GRCh37) including the TdTomato reporter. We used Seurat v.3 to
further process the data. We estimated the doublet rate according to the 10X Chromium guidelines, in proportion to the density of
cells loaded. These rates were used to flag potential doublets based on their gene and UMI counts. Cells with fewer than 800 genes
detected were also filtered out, as well as cells with high percentage of counts mapping to mitochondrial genes (thresholds set by
manual inspection for each dataset, between 25% to 35%). For each experiment, the mutated and corrected samples were merged
and then normalized using SCTransform, with cell degradation effect regressed out. After an initial linear dimensionality reduction
(PCA), we used UMAP projections to represent the data and the Louvain algorithm was used for clustering. Differential expression
tests were done with MAST, applying independent prior to gene testing (minimum detection percentage of 10% in at least one of the
populations, minimum average log-fold change of 0.15 between the two populations). Gene signature enrichment scores for iAT2
markers and cell cycle stage were computed using Seurat. The significance of the differences in these scores between corrected
and mutant samples was tested using Welch Two Sample t tests. The scRNA-seq data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus (GEO; accession number GSE160801).
Proteomic and phosphoproteomic analysis
Cell lysis and trypsin digestion
For proteomic/phosphoproteomic analyses experimental triplicate (n = 3) samples were dissociated for sorting as described previ-
ously. Cells were sorted as described previously for viable (calcein blue+) SFTPCtdTomato+ cells, washed with PBS, pelleted, and
stored at 80C. Cell pellets were thawed and individually placed in 300 ml of lysis buffer composed of 8 M guanidinium chloride
(GuHCl), 50 mM ammonium bicarbonate, 5 mM dithiothreitol (DTT), phosphatase (PhosSTOP, Roche) and protease (Complete,
Mini, EDTA-free Protease Inhibitor Cocktail, Roche) inhibitors and then sonicated on ice using a Branson probe (40 s, in 2 s pulses).
Lysates were alkylated in 12 mM iodoacetamide. Protein concentration was quantified by the Bradford protein assay (Bio-Rad) and
samples were diluted with 7 volumes of 50mMammonium bicarbonate to bring the urea concentration to 1M. Each sample was then
digested overnight at 37C with 2 mg sequencing-grade trypsin (Pierce Trypsin Protease, MS Grade, Thermo Fisher Scientific).




Tandem Mass Tag (TMT) labeling and reserve phase high performance liquid chromatography (LC)
After digestion, the reactions were terminated by adding trifluoroacetic acid (TFA) to 0.1%, de-salted (Waters Sep-Pak), and resus-
pended in 100 mM HEPES buffer. Total peptide concentration was quantified using the Pierce Quantitative Colorimetric Peptide
Assay (Pierce Quantitative Colorimetric Peptide Assay, Thermo Fisher Scientific). Then 100 mg peptide from each sample (volume
adjusted to 100 ml with 100 mM HEPES buffer) was mixed with a unique amine-reactive heavy isotope-coded isobaric TMT (TMT-
11plex) reagent, allowing for multiplex of samples prior to LC/MS. After pooling, the samples were desalted and dried, and a total
of about 0.6 mg of labeled peptide was suspended in 300 ml buffer containing 0.1% ammonium hydroxide and 2% acetonitrile.
This mixture was injected onto a reverse-phase Waters Xbridge C18 HPLC column (Waters) connected to an Agilent 1100 series
HPLC system. Peptides were eluted from the column using a gradient of mobile phase A (2% ACN, 0.1% NH4OH) to mobile phase
B (98% ACN, 0.1% NH4OH) over 48 minutes. Fractions were collected every minute, and every 12
th fraction was pooled, yielding 12
final fractions, each containing approximately 100 mg peptide. Most of each fraction (95%) was set aside for phospho-peptide
enrichment using Fe-NTA magnetic beads (Cube Biotech) while the remaining 5% was analyzed separately by mass spectrometry
as bulk proteome measurements, totaling 24 injections.
Mass Spectrometry (MS)
Fractionated peptide samples were analyzed using a Q Exactive HFX mass spectrometer connected to Easy nLC 1200 ultra
high-pressure chromatography system (Thermo Scientific). Lyophilized peptides were resuspended in mobile phase A solvent
(0.1% formic acid and 2% acetonitrile). The samples were loaded onto a reverse-phase nano-trap column with mobile phase A,
(75 mm i.d. 3 2 cm, Acclaim PepMap100 C18 3 mm, 100Å, Thermo Scientific) and were separated over an EASY-Spray column,
(ES803A, Thermo Scientific) using a gradient (2% to 35% over 120 min) of mobile phase B (0.1% formic acid, 80% acetonitrile) at
a flow rate of 250 nl/min. The mass spectrometer was operated in positive ion mode with a capillary temperature of 275C, and
with a potential of 2100V applied to the emitter. All data were acquired with the mass spectrometer operating in automatic data
dependent switching mode. A high resolution (60,000) MS precursor ion scan (350-1500 m/z range) was performed to select the
12 most intense ions for subsequent fragmentation and MS/MS analysis using HCD (NCE 33 @ 45,000 resolution).
Peptide identification
Resulting RAW files were converted and searched using the MaxQuant platform (version 1.6.7.0; https://maxquant.org/) under stan-
dard settings against the Uniprot human reference protein sequence database (downloaded: April 16, 2019) allowing for two missed
trypsin cleavage sites, variable modifications: phosphorylation at S, T, and Y residues, N-terminal acetylation, and methionine
oxidation. Carbamidomethylation of cysteine residues was set as a fixed modification. Peptide precursor ions were searched with
a maximum mass deviation of 4.5 ppm and fragment ions with a maximum mass deviation of 20 ppm. Peptide and protein identifi-
cations were filtered at 1% FDR using the target-decoy database search strategy. The MaxQuant output files designated ‘‘Phos-
pho(STY)sites’’ and ‘‘ProteinGroups’’ were used for data normalization and other statistical analysis.
Data analysis and pathway enrichment
Bioinformatic analysis was performed using R: A language and environment for Statistical Computing (R Foundation for Statistical
Computing, Vienna, Austria. http://www.R-project.org), version 3.6.1. The protein groups and phosphosite tables from MaxQuant
were filtered to eliminate entries labeled as reverse hits, potential contaminants, and ‘‘only identified by site.’’ Protein quantitation
required at values in at least 70% of TMT channels. The TMT-reporter intensity values were log2 transformed and Loess-normalized.
For differential analysis, the LIMMA (Ritchie et al., 2015) R package was used to fit a linear model accounting for the cell lines. Moder-
ated t tests were corrected with the Benjamini-Hochberg method for FDR. Gene set enrichment analysis was performed using the
fgsea R package (Korotkevich et al., 2019) using the Hallmark (H) and Curated (C2) gene set libraries from MSigDB (Subramanian
et al., 2005) with ranked lists where the gene rank is defined as -log(p value)*sign(log2 fold change) (Reimand et al., 2019). In the
case of duplicate proteins mapping to a common gene symbol, the one with the highest absolute value rank was retained. Heatmaps
were generated with the ComplexHeatmap R package (Gu et al., 2016). The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the Proteomics Identifications (PRIDE) partner repository (Deutsch et al., 2020; Perez-
Riverol et al., 2019) with the dataset identifier PRIDE: PXD022334.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical methods relevant to each figure are outlined in the figure legend. In brief, unpaired, two-tailed Student’s t tests were used
to compare quantitative analyses comprising two groups of n = 3 or more samples, or one-way ANOVAs with multiple comparisons
were used to compare three ormore groups. Further specifics about the replicates used in each experiment are available in the figure
legends. In these cases, a Gaussian distribution and equal variance between samples was assumed as the experiments represent
random samples of themeasured variable. The p value threshold to determine significancewas set at p = 0.05. p value annotations on
graphs are as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Data for quantitative experiments are typically represented as
the mean with error bars representing the standard deviation or standard error of the mean, as specified in the figure legends.
Statistical analysis on imaged alveolospheres was performed using Prism 7 (GraphPad Software, San Diego, CA). Each organoid
was treated as an experimental replicate and unpaired Student’s t test was used to determine statistically significant differences.
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Figure S1. Pro-SFTPC misprocessing and autophagy perturbations in iAEC2s derived from patient-specific iPSCs carrying 
the SFTPCI73T/WT mutation compared to controls generated by CRISPR-mediated gene editing of the SFTPC locus, related 
to Figure 3 and Figure 5.  (A) Chest CT of the SPC6 donor at 3 months of age reveals bilateral diffuse ground glass opacities; CT 
chest of the SPC7 donor at age 12 years reveals bilateral ground glass opacities and traction bronchiectasis. (B) Footprint free 
CRISPR-mediated editing of the SFTPC locus to engineer correction of patient-specific SPC2 iPSCs. The I73T mutation in SFTPC 
exon 3: genomic sequence with the c.218 T>C (p.I73T) mutation is shown in red, the CRISPR guide RNA target sequence shown 
in green, the protospacer adjacent motif (PAM) cutting site in blue, and the oligo-based donor design with corrected base shown in 
red. Pre- and post-correction DNA sequencing chromatograms with yellow boxes show the c.218 mutation site sequence. (C) 
Representative Western blot of SFTPCWT/WT and SFTPCI73T/WT iAEC2 lysates from the iPSC clones described in (B) at the indicated 
differentiation time points for pro-SFTPC (NPRO-SFTPC), mature SFTPB, p62 and LC3 with β actin as loading control. SFTPCI73T/
WT iAEC2s accumulate large amounts of the primary translation product (bracket) and misprocessed intermediate forms 
(arrowhead). In SFTPCWT/WT iAEC2s, both the primary translation product and major processing intermediate forms are detected. 
SFTPCI73T/WT iAEC2s accumulate a larger amount of mature 8 kDa SFTPB. SFTPC I73T/WT iAEC2s demonstrate increased 
accumulation of both LC3 and p62 compared to SFTPCWT/WT iAEC2s, similarly to SFTPCI73T/tdT iAEC2s. See also Figure 5B. (D) 
Representative immunofluorescence microscopy of SFTPCI73T/WT iAEC2s for pro-SFTPC (green), EPCAM (red), and DNA 
(Hoechst, blue) reveals SFTPC protein localized to SFTPCI73T/WT iAEC2 plasma membranes. Scale bars: 10 µm. (E) Representative 
Western blot of  protein lysates from differentiated cultures derived from two additional patient-specific (SPC6 and SPC7) iPSC 
clones, compared to multiple corrected control iAEC2 samples: SFTPCWT/WT, SFTPCI73T/WT, SFTPCtdT/WT and SFTPCI73T/tdT SPC2 
iAEC2 lysates at the indicated time points for pro-SFTPC (NPRO-SFTPC) (left panel) and mature SFTPB (lower panel) with β 
actin as loading control. Both SPC6 and SPC7 iAEC2s produce mature 8 kDa SFTPB and misprocess SFTPC. Longer exposure of 
the SPC6 and SPC7 lanes (right panel) shows that both SPC6 and SPC7 iAEC2s accumulate a higher molecular weight SFTPC 
primary translational product (bracket) and misprocessed intermediate forms (arrowhead) similar to SFTPCI73T/WT and SFTPCI73T/tdT 





















































Figure S2. Paucity of AEC1s in human SFTPCI73T lungs and loss of apical-basal polarity in SFTPCI73T/tdT iAEC2s, related to 
Figure 3. (A) Representative tile scan confocal immunofluorescence microscopy of distal sections of the SPC2 donor and healthy 
donor lung explants stained for RAGE (red), pro-SFTPC (magenta), and DNA (Hoechst, blue). Scale bars: 50 µm. (B) 
Representative confocal immunofluorescence microscopy of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2 cultures for MUC1 (magenta), 
p-ERM (grey), CRB3 (grey), E-Cadherin/CDH1 (green), and DNA (Hoechst, blue) reveals loss of apical-basal polarity in
SFTPCI73T/tdT iAEC2s. Scale bars: 50 µm.
E
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Figure S3. Characterization of gene expression in SFTPCI73T/tdT iAEC2s reveals pathway perturbations and higher 
expression of AEC2 marker genes, related to Figure 4. (A) Clustering of day 114 scRNA-seq transcriptomes in each indicated 
iAEC2 population using Uniform Manifold Approximation Projection (UMAP). All live iAEC2s, irrespective of SFTPCtdTomato 
expression were included. (B) Violin plots showing normalized expression for indicated genes or cell cycle phase in day 114 
SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s by scRNA-seq. (C) Normalized gene expression overlayed on UMAP plots for the 
indicated transcripts or gene sets. (D) RT-qPCR showing fold change in gene expression compared to day 0 (2 (-ΔΔCt)) in day 114 
and day 131 SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s as well as control samples of an adult control human distal lung explant (CTL 
Lung). (mean ± SD; n=3 experimental replicates of independent wells of a differentiation). (E) Gene set enrichment analysis 
(GSEA, Camera of day 113 scRNA-seq from Figure 4A, using HALLMARK gene sets) of significantly upregulated gene sets 
(FDR <0.05) in SFTPC I73T/tdT compared to SFTPCtdT/WT iAEC2s. NES: normalized enrichment score. **p<0.01, ***p<0.001, 



















511-550 nm 401-461 nm Pseudo-colored
Figure S4. SFTPCI73T/tdT iAEC2 lysosomes demonstrate a lower pH when compared to SFTPCtdT/WT iAEC2 
lysosomes, related to Figure 5K. Representative live-cell confocal fluorescence microscopy of SFTPCtdT/WT and 
SFTPCI73T/tdT iAEC2s stained with Lysosensor yellow/blue-dextran and imaged using two filter ranges, 401-461 nm 
(blue) and 511-550 nm (yellow). Subcellular organelles with lower pH are identified as pixels with increased yellow/
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Figure S5. Hydroxychloroquine treatment aggravates the autophagic flux block and metabolic reprogramming in 
SFTPCI73T-expressing iAEC2s, related to Figure 7G, H. (A) SFTPCtdT/WT or SFTPCI73T/tdT iAEC2s were treated with 
either hydroxychloroquine (HCQ; 10 µM) or vehicle (ddH2O) for 18 hours or 7 days. Lysates were subjected to Western 
blotting for LC3 with β actin as loading control. A representative Western blot following HCQ treatment for 7 days is 
shown (n=2 experimental replicates of independent wells of a differentiation). (B) Representative flow cytometry dot plots 
of SFTPCtdT/WT and SFTPCI73T/tdT iAEC2s with or without HCQ (10 µM) treatment and representative live-cell imaging of 
SFTPCtdT/WT and SFTPCI73T/tdT HCQ-treated alveolospheres (bright-field/tdTomato overlay) showing maintenance of the 
AEC2 program (mean ± SD is shown; n=3 experimental replicates of independent wells of a differentiation). Scale bars: 
500 µm. (C) Representative bioenergetics bar graphs plotted as OCR/ECAR ratios under basal conditions or following 
addition of oligomycin (4.5 µM/l) or FCCP (1 µM/l) for SFTPCtdT/WT (black circles) and SFTPCI73T/tdT (purple squares) 
iAEC2s with or without HCQ (10 µM) treatment for 7 days show a significant reduction in OCR/ECAR ratio only in 
























Figure S6. iPSC line characterization, related to STAR Methods. (A) Representative G-banding analyses (SPC2-ST-C11, 
SPC2-ST-B2, SPC2-CorrC1, SPC6, and SPC7 iPSC lines) showing normal (46XY or 46XX) karyotypes. (B) Representative 
immunofluorescence microscopy images showing expression of the pluripotency markers TRA-1-60, TRA-1-81, and SSEA-4 
but not SSEA-1 (as expected for human pluripotent stem cells) in each indicated, undifferentiated iPSC line (ES Cell 
Characterization Kit, SCR001 EMD Millipore).
Table S1. SFTPCI73T Donor Clinical Phenotyping (related to Figure 1 and Figure S1) 
SPC2 SPC6 SPC7 
Age at presentation Late infancy 2 months old Infancy 
Presenting clinical 
phenotype 
Failure to thrive and 






vomiting of feeds, and 
failure to thrive 
Respiratory symptoms 
(details not available) 
CT chest Diffuse ground glass 
opacities and fine reticular 
interstitial infiltrates at 
presentation progressed to 
also include traction 
bronchiectasis and 
honeycombing (Figure 1B) 
Diffuse ground glass 
opacities (Figure S1A) 
Bilateral ground glass 
opacities and traction 
bronchiectasis (Figure S1A) 
Clinical course Treated with corticosteroids 
and weaned to nasal cannula 
supplemental oxygen 
Started on continuous 
supplemental oxygen and 
treated with corticosteroids 
and hydroxychloroquine 
Treated in childhood with 
many years of 
corticosteroids and 
hydroxychloroquine and 
listed for lung transplant but 
not transplanted 
Outcome Progressive respiratory 
failure requiring lung 
transplantation in early 
adolescence 
Has required gastrostomy 
tube feeds and continuous 
supplemental oxygen 
through 3 years of age 
As a young adult, had a 
forced vital capacity (FVC) 
of ~20% predicted 
Other Lung explant histology 
displayed interstitial 
fibrosis, chronic 
inflammation, and alveolar 
remodeling (Figure 1C) 
Has had recurrent 
admissions for respiratory 
symptoms 
Mother of SPC6 donor 
Table S3. Oligonucleotides (related to Key Resources Table) 
TaqMan Gene Expression Assay Primer/Probe Sets 
SFTPC Thermo Fisher Scientific Hs00161628_m1 
SFTPB Thermo Fisher Scientific Hs01090667_m1 
SLC34A2 Thermo Fisher Scientific Hs00197519_m1 
NAPSA Thermo Fisher Scientific Hs00362192_m1 
18S Thermo Fisher Scientific 4318839 
Oligonucleotide primers Integrated DNA Technologies 
SFTPC I73T CRISPR gRNA This paper 5’ CAGGTTCTGGA GATGAGCAC 3’ 
SFTPC I73T Correction single-
stranded oligonucleotide 




SFTPC I73T Correction Forward This paper 5’ GTCGTGGTGAT TGTGGGAGCCCTG 3’ 
SFTPC I73T Correction Reverse This paper 5’ CTGGGCATACC CACCTGCTGGTAG 3’ 
SFTPC I73T Correction 
Sequencing 
This paper 5’ TATGGGGATGG GTACCACTGGCTG 3’ 
tdTomato Targeting Forward (Jacob et al., 2017) 5’ GGGTGAGTGAG CTGATTCGAG 3’ 
tdTomato Targeting Reverse (Jacob et al., 2017) 5’ TGACCTCCTCG CCCTTGCTCACCATG 3’ 
Intact SFTPC Locus Forward (Jacob et al., 2017) 5’ CTACGGACACA TATA AGACCCTGGTC 3’ 
Intact SFTPC Locus Reverse This paper 5’ CAAATAGCCAC CATTCGGACACTC 3’ 
Intact SFPTC Locus Sequencing This paper 5’ TATGGGGATGG GTACCACTGGCTG 3’ 
STEMCCA Excision Forward (Somers et al., 2010) 5’ GGAACTCTTGT GCGTAAGTCGATAG 3’ 
STEMCCA Excision Reverse (Somers et al., 2010) 5’ GGAGGCGGCCC AAAGGGAGATCCG 3’ 
Puromycin Resistance Cassette 
Forward 
(Jacob et al., 2017) 5’ ATGACCGAGTA CAAGCCCACG 3’ 
Puromycin Resistance Cassette 
Reverse 
(Jacob et al., 2017) 5’ TCAGGCACCGG GCCTGC 3’ 
Mki67 Forward This paper 5’ ACCATCATTGACCGCTCCTT 3’ 
Mki67 Reverse This paper 5’ GCCCTGATGAGTCTTGGCTA 3’ 
Top2a Forward This paper 5’ TACAGTGCTCAACCTCTGACG 3’ 
Top2a Reverse This paper 5’ GGGATCTCGTGTTGGGAAGG 3’ 
